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Abstract 
Tumor necrosis factor alpha (TNFα) is a potent antitumoral cytokine, but its high 
intrinsic toxicity precludes systemic treatment. Here we demonstrated localized 
antitumor activity of TNF concomitant with decreased vessel density (CD31 
expression) after systemic injection of TNF coding polyplexes using a non viral, 
biodegradable gene carrier (G3-HD-OEI) exhibiting intrinsic tumor affinity in 
vivo in murine neuroblastoma model. We used a novel plasmid vector with CpG 
free backbone and an optimized promoter-enhancer combination led to 
sustained and high TNF-α transgene expression in vitro on Neuro2A murine 
neuroblastoma cells. Secreted TNF-α induced high cytotoxicity on L929 
indicator cells and increased endothelial cell permeability in a transwell system. 
Synthetic gene carriers allowed tumor restricted transgene expression after 
intravenous injection either by passive accumulation of the gene carrier within 
the tumor or by specifically targeting the epidermal growth factor receptor. 
Systemic TNF gene delivery promoted tumor accumulation of liposomally 
encapsulated doxorubicine (Caelyx®) in subcutaneous Neuro2A murine 
neuroblastoma and HUH7 human hepatocellular carcinoma by enhancing 
tumor endothelium permeability. TNFα gene therapy was combined with 
liposomal doxorubicine (Caelyx®) for the treatment of subcutaneous and 
metastatic murine neuroblastoma and metastatic human colon 
adenocarcinoma. The combined chemo- and gene therapy synergized in 
antitumoral activity: both, subcutaneous tumors and tumor metastases 
responded to the treatment with significant tumor growth delay. Also tumors 
re-growing after initial treatment were successfully treated in a second cycle 
pointing at the absence of resistance mechanisms. This schedule opens the 
possibility for the treatment of solid tumors otherwise not accessible for 
macromolecular drug carrier. 
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1. Introduction 
1.1. Gene therapy 
1.1.1. Introduction to gene therapy 
Genes - the biological units of heredity, which recent have been better 
understood and manipulated well, have set the stage for scientists to alter 
patients' genetic material by this experimental technique to fight or prevent 
disease. Since late 1970s, gene therapy rather quickly developed. Gene 
therapy offers a new treatment paradigm for curing human disease. Gene 
therapy is a promising treatment option for a number of diseases, such as 
cancer, peripheral vascular disease, arthritis and other acquired diseases, but 
the technique is still highly experimental and under study to make sure that it 
will be safe and effective. Up to now, there are still many problems should be 
overcome before gene therapy becomes a common technique for treating 
disease. The success of gene therapy is largely dependent on an efficient and 
safe gene transfer to the host cells or tissue and the appropriate expression of 
the introduced gene. In order to treat cancer and other diseases effectively with 
gene therapy, researchers have to develop gene delivery vectors that can 
specifically focus on the target cells located throughout the body and without 
any seriously side effect and the related gene expression system. There will be 
no ―universal vector‖, and each clinical indication may require a specific set of 
technical hurdles to overcome, such as cell-based gene delivery technologies 
and so on (M.Rubanyi 2001).  
 
1.1.2. How is gene therapy being studied in the treatment of cancer? 
Normally, to keep our body healthy, cells grow and divide as part of the normal 
process of cell regeneration. However, sometimes the genetic material (DNA) 
of a cell are damaged, producing mutations that affect normal cell growth and 
division and the cells in our body do not die when they supposed to, but more 
cells are formed. These extra cells may develop into tumor. Nearly all cancers 
are caused by genetic material mutation in cells. 
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Surgery, radiotherapy and chemotherapy are three conventional modalities to 
treat cancer, but they are often unsuccessful in treating cancer. As the 
development of gene therapy, it is becoming the fourth modality for cancer 
treatment. In one approach, researchers replace missing or altered genes (e.g., 
p53 and some other cancer suppressing or apoptosis inducing genes) (Schmitt; 
2002). Another approach is to improve a patient's immune response to cancer 
by stimulating the body's natural ability to attack cancer cells, since cancer 
patients generally have lowered immune response. Various genes, mainly 
encoding for cytokines, co-stimulatory molecules and growth factor can modify 
tumor cells as well as immune effector cells. Genes coding for cytokines have 
also been used to enhance the immune response against the tumor cells 
(Kikuchi 2000). Cytokines currently being tested in cancer vaccine trials include 
IL-2, IL-4, IL-7, tumor necrosis factor (Wagner 2004), interferon-γ and GM-CSF. 
A constant supply of oxygen, nutrients, hormones and growth factors can be 
provided after formation of new blood vessels or angiogenesis for the growth 
and dissemination of tumors. It has been shown that inhibiting angiogenesis 
regresses experimental tumors thus being a suitable target for gene therapy 
(Huang 2001). Also, to make them more sensitive to chemotherapy, radiation 
therapy, or other treatments, scientists are studying the insertion of genes into 
cancer cells. Besides, DNA vaccination, which means that the naked plasmids 
DNA which contains genes coding for tumor-specific antigens were injected 
and commence synthesizing the protein intracellularly, is also one of the 
approaches of gene therapy for the treatment of cancer (Benton 1998). 
Cancer gene therapy approaches could be either applied as single-agent 
therapy or combined with an established conventional treatment regimen such 
as chemotherapy or radiotherapy, which might lead to greater therapeutic effect. 
Up to now, gene therapy for cancer is still a challenge and the success of this 
treatment modality will ultimately depend upon the ability to target delivery to 
cancer cells, express the gene of interest at high levels and minimize toxicity by 
targeting transgene expression to specific cells. The concept of cancer-specific 
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gene therapies are becoming more viable and promising since the 
development in cell and molecular biology and the advances in bioinformatics. 
 
1.2. Tumor necrosis factor (TNFα) 
1.2.1. Introduction to TNFα 
Tumor necrosis factor (TNF, structure shown in fig. 1), is primarily produced as 
a 212-amino acid-long type II transmembrane protein arranged in stable 
homotrimers, which upon cleavage by the metalloprotease TACE produces a 
soluble trimer of 157 amino acids (Killar L 1999; Lejeune 2006). Both isoforms 
of TNF (membrane and soluble TNF) bind two distinct receptors that are 
ubiquitous, TNFR-1, and TNFR-2 (Dembic Z 1990). As show in fig. 2, 
evidences for two opposing pathways were found in endothelial cells: one is 
leading to caspase activation (Lin 1999), which is dependent on the activation 
of TNFR-1 (Wong 1994). It is an apoptotic pathway initiated by the clustering of 
death domain containing proteins (Tartaglia 1993; Grell 1994; Rath 1999). The 
other one is a proliferation and survival pathway involving the activation of 
nuclear factor NF–κB (Hsu 1996; Rath 1999; Horssen 2006). As a major 
inflammatory cytokine involved in systemic inflammation, the primary role of 
TNF is the regulation of immune cells. However, TNF is also believed to induce 
rapid haemorrhagic necrosis of experimental cancers. TNF is able to induce 
apoptotic cell death, induce inflammation, and to inhibit tumorigenesis and viral 
replication. A variety of human diseases, including major depression (Dowlati 
2010), Alzheimer's disease (Swardfager 2010) and cancer (Locksley 2001) 
could be resulted due to dysregulation of TNF production. 
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Fig. 1, the structure of TNF  protein  (Figure from (Lejeune March 2006)) 
 
 
 
Fig. 2: Tumor necrosis factor receptor 1 (TNFR-1) signaling pathway, (figure from 
(Horssen 2006)). 
 
1.2.2. The timeline of the work on TNFα and cancer treatment 
In around 1890s, Dr. Coley and other investigators developed a treatment for 
malignant tumors by injections of bacterial toxins and found that intercurrent 
bacterial infections were said to have elicited profound effects upon malignant 
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tumors (Nauts 1945; Balkwill 2009). In 1944 Shear et al. isolated 
lipopolysaccharide from bacterial extracts and showed that this was 
responsible for tumor regression in a mouse model of cancer (Shear 1944; 
Balkwill 2009). In around 1962, to reduce the often lethal effects of endotoxin or 
other bacterial products, O‘Malley et al. isolated serum from endotoxin treated 
animals to treat animals with experimental cancers. The serum also caused 
tumors necrosis, leading to the conclusion that it contained a ―tumor necrotizing 
factor‖ (O‘Malley 1962; Balkwill 2009). In 1975 came a major advance, since Dr. 
Carswell et al reported that it was an endotoxin-induced serum factor which 
then was named ―tumor necrosis factor‖ that causes necrosis of tumors 
(Carswell 1975). From 1984 until present, identification and characterization of 
other members of the TNF and TNF receptor families were performed by 
scientists around the world which enabled the development of a number of 
research tools, including gene-deleted mice (Gray 1984; Locksley 2001; 
Ashkenazi 2002). In 1987, first clinical trials with TNF were performed in 
advanced cancer (Blick 1987; Kimura 1987; Selby 1987; Creagan 1988). In 
1984 and 1985, human and mouse TNF genes were cloned (Pennica 1984; 
Marmenout 1985). Between 1984 and 1988, scientists found that local 
treatment with recombinant TNF causes tumor necrosis in a range of mouse 
models (Pennica 1984; Balkwill 1986; Brouckaert 1986; Talmadge 1988). 
However, locally and repeatedly injection of TNF should be perfomed for 
optimal activity, even though there still was a risk of regrowth at the periphery of 
the lesion. However, when recombinant mouse TNF was given to mice, it 
caused symptoms similar to high doses of endotoxin (Brouckaert 1986; 
Kettlehut 1987; Havell 1988). To decrease this toxicity, in 1992s surgeons 
Ferdy Lejeune, Alexander Eggermont and their colleagues performed a local 
approach of TNF therapy by isolated limb perfusion (ILP), to deliver high doses 
of TNF in combination with IFN γ and melphalan locoregionally to patients with 
cancers of the extremities. Specific destruction of tumor vasculature, 
haemorrhagic necrosis and complete tumor disappearance were observed in 
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patients with advanced soft tissue sarcomas or melanoma due to this treatment 
(Lienard 1992; Grunhagen 2006). As the results of further refinements and 
studies into mechanisms of action in animal models suggested, with mild 
hyperthermia optimizing the anti-tumor effect, TNF synergized with melphalan 
chemotherapy for cancer treatment in a rat osteosarcoma ILP model (de Wilt 
1999), while TNF alone was ineffective in this setting. A combination of TNF 
and doxorubicin had comparable effects in rat sarcoma models (van der Veen 
2000). It appeared that tumor blood vessel permeability was enhanced upon 
TNF treatment, leading to tissue concentrations of chemotherapy augmenting 
and the tumor vasculature destroying (Seynhaeve 2007). 
 
1.2.3. Clinical trials with recombinant TNFα 
It was the expectation of many scientists that recombinant human TNF would 
be an important new treatment for cancer patients. In 1987, First clinical trials 
with TNF were performed in advanced cancer (Blick 1987; Kimura 1987; Selby 
1987; Creagan 1988). Unfortunately, systemic TNF administration always 
causes severe toxicity. Thus, local administration of TNF is necessary instead 
of systemic treatment. As mentioned in section 1.2.2 , to decrease this toxicity, 
in 1992 a local approach of TNF therapy isolated limb perfusion (ILP) to deliver 
high doses of TNF in combination with IFNγ and melphalan locoregionally, to 
patients with cancers of the extremities were performed by surgeons Ferdy 
Lejeune, Alexander Eggermont and their colleagues. Base on encouraging 
results of research and clinical trials, in Europe in 1999, TNF (tasonermin) was 
licensed specific for the treatment of irresectable soft tissue sarcoma of the 
limbs used in combination with melphalan via mild hyperthermic ILP. 
 
1.2.4. If TNFα could be a treatment of cancer, how does it work? 
The mechanism how TNF function in tumor therapy might be complicated. At 
first it was thought that TNF was also directly killing the malignant cells in the 
animal models of cancer. TNF is considered as a cytokine involved in a 
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receptor-triggered signaling pathway that leads to apoptosis (Urs von Holzen 
2005 ). As mention in section 1.2.1, evidences for two opposing pathways were 
found in endothelial cells: one leading to caspase activation(Lin 1999), which is 
dependent on the activation of TNFR-1(Wong 1994), it is an apoptotic pathway 
initiated by the clustering of death domain containing proteins (Tartaglia LA 
1993; Grell M 1994). Recombinant TNF was reported to be toxic for cancer 
cells in tissue culture studies (Colotta 1984). However, many of these data 
suggest that the cytotoxic potential of TNF is unmasked only in combination 
with metabolic inhibitors such as mitomycin C, cyclohexamide or actinomycin D 
(Colotta 1984; Sugarman 1985; Dealtry 1987) or in combination with 
interferon-γ (IFN γ) (Williamson 1983; Fransen 1986). The asscociated 
mechanism could be that the metabolic inhibitors inactivate the intracellular 
survival and inflammatory pathways downstream of TNF signaling, thus 
allowing apoptosis to proceed. A large number of evidences suggest that the 
antitumor activity of TNF depends on selective destruction of the 
tumor-associated vascular bed and TNF-induced alteration of endothelial 
barrier function and of immune mechanisms rather than having toxic effects 
directly on tumor cells (Nawroth 1986; Palladino 1987; Nawroth 1988; Clauss 
1990; Gasparri 1999). One explanation of the mechanism shared by Horssen is 
shown in fig 3. (Figure and legends from (Horssen 2006)). The double-induced 
hyperpermeability (by tumor endothelium and by TNF mediate permeability 
enhancement), along with the dual targeting—the tumor-associated 
vasculature (TAV) (by TNF-α) and the tumor cells (by the chemotherapy 
drug)— might explain the observed synergy between TNF and chemotherapy 
in locoregional treatment of patients with advanced tumors of the limb (Lienard 
1999; Horssen 2006). Thereof, after patients were given isolated limb perfusion 
with TNF in combination with interferon-and melphalan, it was observed that 
the macro- and microvasculature of tumors, but not of normal tissue, to be 
extensively damaged (Eggermont 1996). Alberto Mantovani‘s group reported 
that TNF changed the perception of the tumor vasculature by activating 
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endothelial cells in a gene expression-dependent way (Mantovani 1989). 
Besides, the mouse experiments did reveal a role for T cells in the anti-tumor 
actions of TNF. There was a diminished anti-tumor effect of TNF in T 
cell-deficient mice (Havell 1988) and T cell mediated immunity developed in 
animals cured of the Meth A sarcoma by TNF (Palladino 1987). TNF is an 
important effector molecule in stimulation of the cellular immune response and 
direct cytotoxicity to tumor cells (Urs von Holzen 2005 ),  like CD8+ T cell and 
natural killer (NK) cell killing of immunogenic tumor cells (Kashii 1999; 
Prevost-Blondel 2000). 
 
Fig. 3: A proposed mechanism of the tumor necrosis factor alpha (TNF-α) effect  
(figure and description from (Horssen 2006)) 
(A): Scheme of a vessel with healthy endothelial lining (upper) and tumor endothelial lining 
(lower). There are differences between healthy vascular and tumor vascular. The healthy 
endothelium is with low permeability and extravasation tightly organized since it is consists 
with a continuous lining of endothelial cells, pericytes and a thin basement membrane. In 
contrast, tumor endothelium is greater permeability, since it is consists with uncontinuous 
lining of endothelial cells, lacks pericyte coverage while the basement membrane is 
thickened. Besides, a higher TNFR-1 expression level induced by TNFR-1–upregulating 
factors (produced by vessel-surrounding cells) is exhited on tumor endothelium. So, the 
tumor vessels are specific target for TNF-α treatment due to the high level of TNFR and the 
specific architecture of the endothelial lining. Fig. B: Upon TNF-α treatment, tumor 
endothelium binds TNF-α, which induces apoptosis in some endothelial cells leading to an 
enormous induction of vessel permeability. As a result, the chemotherapy drug is well 
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distributed throughout the tumor, and destroys the tumor cells and the tumor develops 
hemorrhagic necrosia due to a strong extravasation of erythrocytes (figure and legend from 
(Horssen 2006)). 
 
1.2.5. TNFα in cancer: target or treatment? 
Although many researchers found the powerful ability of TNF as cancer 
treatment, we still have to ask: was the research of the previous 40 years 
correct? Did recombinant TNF cause tumor necrosis in mouse cancer models?  
However, since 1990, many adverse findings emerged in large number.  In 
1989–1993, scientists found that TNF may increase experimental cancer 
growth and spread (Malik 1989; Malik 1990; Orosz 1993). By the mid 1990s it 
was becoming clear that macrophage-derived TNF play a crucial role in 
inflammation and tumor development (Oguma 2008; Popivanova 2008). It was 
found in an in vitro model of colorectal cancer that TNF in the tumor 
microenvironment may also induce the epithelial – mesenchymal transition of 
malignant cells (Bates 2003), which may partly explain the ability of TNF to 
increase the metastastic activity of tumor cells first reported in the 1990s. In 
1999, scientists found that TNF-knockout mice are resistant to skin 
carcinogenesis. In 2003–2008, scientists found anti-TNF antibodies or 
antagonists inhibit murine cancer growth involving carcinogen-induced, 
transplantable xenograft and genetic models of common epithelial cancers 
(Scott 2003; Rao 2006; Egberts 2008; Popivanova 2008). In 2004, a first clinical 
trial with TNF antagonists was performed in cancer patients (Madhusudan 
2004). The accumulating evidences were that TNF was not only made by 
cancer cells in tissue culture but was also present in the tumor 
microenvironment of many cancers, raising the possibility that it might actually 
be enhancing cancer growth.  
Is TNF the key to this endeavour? It could be like many scientists indicated, low 
concentrations of TNF-a have been shown to promote proliferation of 
endothelial cells (Frater-Schroder 1987; Fajardo 1992) while higher 
concentrations are cytotoxic to, and result in apoptosis of, endothelial cells both 
in vitro and in vivo (Frater-Schroder 1987; Sato 1987; Fajardo 1992; 
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Polunovsky 1994). Anyway, as Dr. Frances Balkwill has suggested in Nature 
Reviews on Cancer, TNF probably holds greater promise for further clinical 
development when used in combination with other cancer treatments. Besides, 
whether pro- or anti-tumoral, there is no doubt that TNF is important to cancer 
biology and treatment (Balkwill 2009). 
 
1.3. Novel plasmids for gene therapy 
1.3.1. pTNF -  the novel plasmid with CpG free backbone and human CMV 
as enhancer 
Here we used pTNF, a novel TNF encoding plasmid with CpG free back bone 
and hCMV as enhancer. Viral promoters and enhancers are common features 
in plasmid design, and the most extensively used originates from the 
cytomegalovirus (CMV). The close interrelation and still distinct functionality of 
the CMV enhancers has been demonstrated by replacing the enhancer of the 
murine CMV (mCMV) with the hCMV enhancer in vitro without changing the 
wild-type characteristic growth of mCMV in murine cells (Angulo A. 1998). 
However, replacing the enhancer of hCMV with the murine analogue resulted in 
less efficient replication in human cells (Isomura 2003). The CMV promoter 
might still be the most commonly used promoter since it renders strong and 
ubiquitous expression. But because of the reported fast inactivation by 
promoter methylation (Collas 1998; Brooks 2004) other ubiquitous promoters 
are being investigated, for example the promoter of the elongation factor 1α 
(EF-1) or β-actin gene (Alexopoulou A.N. 2008). Thus, the plasmid vectors here 
carry a hCMV enhancer and an EF-1 promoter. Some transgene vectors are 
silenced by the host cell, or even disposed of by the immune system, although 
they own strong and efficient promoter and enhancer element. These are 
caused by specific unmethylated CpG dinucleotides commonly found in 
bacterial DNA, which can elicit a direct inflammatory response. This effect has 
been harnessed to improve the immune response after vaccination by using 
CpG-motifs as adjuvants (McCluskie 2000; Kumagai 2008) or for cancer 
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immune therapy approaches (Wooldridge 2003). It was shown that 
CpG-dinucleotides in the plasmid DNA have a strong negative effect on the 
duration of transgene expression (Yew 2000; Yew 2002; Hodges 2004; Mitsui 
2009). Even as few as one CpG dinucleotide in the plasmid DNA sequence can 
lead to increased levels of pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ) 
and infiltrating neutrophils; additional CpG s´ increase these levels 
incrementally, whereas CpG-depleted plasmids shows no measurable 
elevation of the cytokine levels (Hyde 2004). Stephen C Hyde et al 
demonstrated that retention of even a single CpG in pDNA is sufficient to elicit 
an inflammatory response, whereas CpG-free pDNA vectors do not. Using a 
CpG-free pDNA expression vector led to sustained (≥56 d) in vivo transgene 
expression in the absence of lung inflammation (Hyde 2004). The mechanism 
by which unmethylated CpG-sequences reduces transgene expression is not 
entirely clear yet. Because of the disadvantageous effects of CpG s´ in the 
plasmid vector such as activation of the immune system or silencing of the 
transgene and in the context of gene therapy where a long-term transgene 
expression is desired, CpG-free backbone design is helpful, thus we tried to 
design a plasmid with CpG-free backbone. 
 
1.3.2. pRGD-TNF - plasmid targeting TNF expression by employing 
sequence of vasculature-targeting motif RGD  
The vascular effects of TNF mentioned above in section1.2.4 provide the 
rationale for developing vasculature-targeting strategies aimed at increasing 
the therapeutic index of this cytokine. Recently several peptides that can bind 
receptors expressed within angiogenic vessels have been selected by in vivo 
phage display. Among the various peptides identified so far, CNGRC and 
CDCRGDCFC, containing Asn-Gly-Arg (NGR) or Arg-Gly-Asp (RGD) motifs, 
have been used for targeting chemotherapeutic drugs, proapoptotic peptides, 
and cytokines to tumors in experimental models (Arap 1998; Zarovni 2004). 
Flavio Curnis and colleagues report that coupling TNF to CNGRC, a CD13 
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ligand capable of ―homing‖ to tumor vessels (Curnis 2000) enhances the 
immunotherapeutic properties of TNF and improves its therapeutic index in 
lymphoma and melanoma animal models. Natasa Zarovni also showed that by 
fusing the TNF sequence with those of peptides able to target tumor vessels 
such as CNGRCG or ACDCRGDCFCG, the therapeutic properties of the TNF 
gene are improved, while the treatment did not result in any side effect (Zarovni 
2004), which indicated vascular targeting with TNF coupled to tumor-homing 
peptides is rationale. Thus, here we try to investigate the therapeutic potential 
of a plasmids encoding TNF fused to the C terminus of ACDCRGDCFCG 
(pRGD-TNF) and compare them with plasmid pTNF. 
 
1.3.3. pTNF-miR143 - plasmid selective TNF expression by employing 
miRNA-143 targeting sequence  
MicroRNAs (miRNAs) represent a class of small nucleotides (20–25 bp) which 
are typically excised from 60–110 nucleotide hairpin RNA precursor structures. 
They regulate gene expression by repressing translation of target cellular 
transcripts and play a crucial role in regulating many cellular events, including 
the balance between proliferation and differentiation during tumorigenesis and 
organ development (Calin 2006; Kloosterman 2006; Zhao 2007; Kimberly 
2009). In May 2006, a group led by Dr. Luigi Naldini and Dr. Brian Brown in 
Milan, Italy reported that they developed a way to prevent the immune system 
from rejecting a newly delivered transgene by utilizing the natural function of 
miRNA to selectively turn off the expression of their therapeutic gene in cells of 
the immune system and prevent the gene product from being found and 
destroyed. Their results provide novel evidence of miRNA regulation and 
demonstrate a new paradigm in vector design with applications for genetic 
engineering and therapeutic gene transfer (Brown 2006). It was also reported 
that miR-143 is the most enriched miRNA during differentiation of mouse 
embryonic stem (mES) cells into multipotent cardiac progenitors (Ivey 2008), 
but down regulated in various cancer cell lines, colon cancers, and lung 
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cancers (Budker 1996; Kimberly 2009). In view of the natural function of 
microRNA, pTNF-mir143 was constructed by Dr. Rudolf Haase in our lab by 
inserting miR-143 targeting sequence (5 copies of sequence 
GAGCTACAGTGCTTCATCTCA) into plasmid pTNF (at 3' untranslated region 
of gene TNF). Thus, the expression of the therapeutic gene should be 
selectively turned off in cells which are rich in miR-143 (almost all organs are 
miR-143 rich) through miRNA specifically repression, while not affecting the 
transgene expession in the tissues low miR-143, such as various cancer cells. 
 
1.4. Approaches for gene delivery 
How are genes transferred into cells so that gene therapy can take place? In 
the past few years during the development of gene therapy, various methods 
have evolved to transfer genes to the target cells. In focus have been physical, 
chemical, and biological principles to develop safe and efficient method that 
delivers a transgene into target cells for appropriate expression. For the gene 
transfer basically two major branches exist: viral and non-viral vectors. 
 
1.4.1. Viral vectors for gene transfer 
Viruses are the most commonly used vectors in gene therapy. So far, the most 
widely used and also perhaps efficient method of gene transfer is by means of 
viral vectors. Over the years, viruses have evolved to enter the cell and 
efficiently used the cells to make its own viral proteins. Viruses include 
retroviruses lentiviruses, poxviruses, adenoviruses, herpes viruses and 
adeno-associated viruses are ubiquitous used as vectors for the desired gene 
delivery in many researches and early clinical trials for gene therapy. Since 
these viruses differ in characteristics, researchers may use different vectors 
according to the specific characteristics and requirements of the study. Viruses 
are quite effecint in gene delievery, however, even the most efficient gene 
transfer vectors in use today, have certain disadvantages. One of the major 
disadvantages is decreased effectiveness during repeated treatments in vivo 
Introduction                                                                                                                                                        14 
due to immunogenicity of viral vectors. Thus, many non-viral approaches for 
gene delivery are developing to conquer these problems. 
 
1.4.2. Non-viral approaches for gene delivery 
Despite efficient transgene transfection potential of viruses, their utility in clinic 
is severely limited due to several disadvantages such as immunogenicity of 
viral proteins, risk of oncogenesis, insertional mutagenesis, dose limiting 
hepatotoxicity and inadvertent creation of infectious viral particles (Gao 2007; 
Russ 2007; Pathak 2009). Hence, to avoid these disadvantages of the viral 
vectors for gene delivery, the non-viral approaches have been extensively 
studied. Nonviral gene delivery approaches consist of physical approaches 
(carrier-free gene delivery) and chemical approaches (synthetic vector-based 
gene delivery). 
Physical approaches is charactered by permeating the cell membrane by a 
physical force which then facilitates the intracellular gene transfer by diffusion 
(Gao 2007). Physical approaches include naked DNA injection, electroporation, 
gene gun, ultrasound, Jet injection, Magnetofection, Photochemical 
internalization (PCI), and hydrodynamic delivery (Wagner 2004). 
The chemical approaches use synthetic or naturally occurring compounds as 
carriers to deliver the transgene into cells. Till now, encapculation of DNA into 
condensed particles by using cationic lipids or cationic polymers are the most 
frequently studied strategy for nonviral gene delivery.  
Several polymers have been explored as non-viral vectors for delivery of DNA. 
The polymer can package DNA into nanoparticles, protect it from degradation 
and enhance its binding to cells and transport into the cytoplasm. Over the 
years, a significant number of cationic polymers, such as polyamidoamine 
(Haensler 1993), polyethylenimine (PEI) (Boussif 1995), polyallylamine, and 
polypropylamine dendrimers (Schatzlein 2005), chitosan (Venkatesh 1997), 
cationic proteins (polylysine, protamine, and histones) (Balicki 1997), cationic 
dextran (Hosseinkhani 2004), and cationic peptides (Balicki 2002; Park 2003) 
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have been explored as carriers for in vitro and in vivo gene delivery. Cationic 
polymers differ dramatically in their transfection activity and toxicity, while 
sharing the function of delievering the DNA into the cell. PEI, which is perhaps 
the most active and most studied polymer for gene delivery, was first introduced 
in 1995 (Boussif 1995). The non-biodegradable nature of PEI might be one 
disadvantage for its use as a transfection reagent (Fischer 2003). PEI 
oligomers owing high transfection efficiency can be generated through 
cross-linking of low-molecular weight PEI with bifunctional reagents. It was 
shown that transfection activity can been significant increased by conjugation of 
lytic peptides (melittin) to 25 kDa PEI (Ogris 2001 ; Boeckle 2006). The surface 
charge of PEI can be dramatically reduced by surface modification with PEG, 
thus the tendency to form large aggregates in the serum is also reduced. To 
provide shielding to polyplexes, scientists try to conjugate PEI with a ligand, 
such as transferrin, antibody, sugar moieties, or avidin, and the conjugation 
also leads to the possibility of target-specific gene delivery (Kichler 2004 ). To 
reduce the toxicity associated with cationic polymer-based gene delivery 
systems, more biodegradable cationic polymers have been designed. 
 
1.4.3. Polymer G3-HD-OEI/G2-HD-OEI and polymer LPEI-PEG-GE11 
The challenge for in vivo gene delivery is to pinpoint the limiting factors and 
implementation strategies to enhance gene delivery efficiency with minimal 
tissue damage. A major challenge for non-viral gene delivery systems is the 
efficient targeting of these genes to the specific tissue such as tumor to reduce 
side effects like tissue damage. When developing non-viral vectors, scientists 
found that oligocations transfected as efficient as PEI 25 k but were significantly 
less toxic to cells after cross-linking of small PEI or PPI with a biodegradable 
bond such as a disulfide or ester bond (Gosselin 2001; Forrest 2003). Careful 
modifications by conjugation of relatively bulky groups (proteins, such as EGF, 
transferrin; peptides, such as GE11; PEG) or smaller groups (sugar, small 
polymers, acyl group) to reduce a portion of the positive charges have yielded 
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PEI derivatives that are more efficient in transfection and less toxic to cells 
(Kichler 2004 ). 
Several grafted polypropylenimine dendrimers were synthesized by Dr. Verena 
Russ in our lab through modifying either polypropylenimine (PPI) dendrimer 
generation 2 (G2) or generation 3 (G3) via 1.6-hexandioldiacrylate with 
branched oligoethylenimine 800Da (OEI) or PPI dendrimer G2-, as the 
structure shown in fig. 4 (Russ 2008). All grafted dendrimers display an 
advantageous biocompatibility profile compared to LPEI or BPEI, since no 
erythrocyte aggregation after incubation with plain polymer occurred while 
OEI-grafted dendrimers are moreover biodegradable resulting in low toxic 
metabolites. Transgene expression was predominantly found in the 
(subcutaneous) tumors in tumor-bearing mice upon i.v. injection of OEI-grafted 
dendrimer polyplexes (the transfection level for G3-HD-OEI is 12-fold higher) 
(Russ 2008). Importantly, the tumor gene expression levels significantly 
increased with the higher dendrimer core generation. All these results show 
that OEI-grafted polypropylenimine dendrimers is a degradable and 
biocompatible vectors which is very attractive for further investigations. 
G2-HD-OEI was used as systemic nonviral delivery agent of the sodium iodide 
symporter gene for targeted radioiodine therapy of neuroblastoma tumors, and 
exhibits high transfection efficiency in tumors (Klutz 2009). 
 
Fig. 4: Schematic structure of G2-HD-OEI (Russ 2008) 
Targeted therapy for cancer has gained momentum during the past decade. 
Many cancer cells such as glioblastoma and hepatocellular carcinoma cell lines 
show epidermal growth factor receptor (EGFR) over-expression. Thus, EGF 
could be a targeting part of vectors to specifically deliver the therapeutic genes 
to cancer cells. Dr. David Schaffert in our lab found that the optimized 
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LPEI-PEG2kDa-EGF conjugate displays reduced chemical complexity and 
efficient poly(I:C)-mediated killing of EGFR overexpressing tumors in vitro and 
in vivo (Schaffert 2011). One simplification was done in our lab with the vector is 
that EGF is replaced by a 12 amino acid peptide (GE11), which binds to the 
EGFR with 40 nM affinity and is able to internalize with the receptor (Li 2005). 
LPEI-PEG-GE11 is based on linear polyethylenimine carrying a peptide (GE11) 
selectively binding to the epidermal growth factor receptor, the efficacy of these 
conjugates in poly (I:C)-mediated cell killing was evaluated in vitro using two 
human U87MG glioma cell lines and showed that the GE11 vector has a similar 
or even better performance as EGF vector. It will simplify vector production, 
reduce markedly production costs, and may have fewer side effects. 
LPEI-PEG-GE11 was used as systemic nonviral delivery agent of the sodium 
iodide symporter gene for targeted radioiodine therapy of hepatocellular 
carcinoma (HCC) (HuH7), and exhibits high transfection efficiency in tumors 
(Klutz 2011). So here, we employed LPEI-PEG-GE11 as gene carrier in the 
HUH7 tumor model. 
 
1.5. Chemotherapeutics 
1.5.1. Chemotherapy 
Chemotherapy is the treatment of cancer with anticancer drugs. Chemotherapy 
with the main purpose of killing cells is usually used in patients with cancer that 
has already metastasized. Chemotherapy can cure some types of cancer, while 
in some cases it is used to slow the growth of cancer cells or to prevent the 
metastasis of the tumor cells after surgery. Most chemotherapy drugs interfere 
with the ability of cells to grow or multiply. Chemotherapy is usually given as an 
adjuvant in addition to other cancer treatments, such as surgery and radiation 
therapy. The use of two or more drugs together often works better than a single 
drug for treating cancer. This is called combination chemotherapy.  
 
1.5.2. Doxorubicin and Liposomal formulation 
Introduction                                                                                                                                                        18 
Doxorubicin (trade name Adriamycin; also known as hydroxydaunorubicin) is 
used to treat a wide range of cancers, such as breast cancer, stomach cancer, 
lymphoma, leukemia, multiple myeloma, bone cancer, and ovarian cancer 
(Ozturk 2011). It is an antitumor antibiotic, which are made from natural 
substances such as fungi in the soil. In the 1950's, the drug was originally 
isolated from bacteria found in soil samples taken from an Italian castle - Castel 
del Monte. Doxorubicin slows or stops the growth and spread of cancer cells in 
the body. Doxorubicin's most serious adverse effect is life-threatening heart 
damage (Ozturk 2011). Doxorubicin showed good activity against murine 
tumors, especially solid tumors. Although it is thought to interact with DNA by 
intercalation, the exact mechanism of action of doxorubicin is complicated and 
still somewhat unclear (Fornari 1994). 
To reduce systemic toxicity caused by anticancer agents while retaining or 
even improving in vivo efficacy, scientists try to encapsulate them into 
pegylated, long circulating liposomes (Papahadjopoulos 1991; Lasic 1996; 
Hagen 2002; Seynhaeve 2007). These liposomes tend to accumulate in tumors 
by leaking through the often-compromised tumor vasculature since their small 
size, long circulation time, and reduced interaction with serum proteins 
(Gabizon 1992; Wu 1993; Seynhaeve 2007). There are two liposomal 
doxorubicin drugs that work in slightly different ways and are used to treat 
different types of cancer, Caelyx® and Myocet®. 
Caelyx® (Doxil) is a novel pegylated liposomal formulation of the 
first-generation anthracycline, doxorubicin made by Ben Venue Laboratories for 
Johnson & Johnson in the United States. It was developed to treat some types 
of cancer, among which, the most commonly ones are ovarian cancer and 
Kaposi's sarcoma, an AIDS-related cancer that causes lesions to grow under 
the skin. Recently its therapeutic effect in the treatment of metastatic breast 
cancer, as well as recurrent squamous cell cervical carcinoma, soft tissue 
sarcoma, prostate cancers and others was investigated (Tejada-Berges 2002). 
The length of the treatment and the number of cycles the patients are treated 
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with depend on the type of cancer. The substitution liposome-encapsulated 
doxorubicin for doxorubicin would be desirable because 
liposome-encapsulated doxorubicin are less cardiotoxic than unencapsulated 
doxorubicin and also have enhanced efficacy in some solid tumors compared 
with free doxorubicin, due to their higher accumulation in  the target solid 
tumors by passing the tumor asscoatied vasculature which exhibit higher 
permeability than healthy vasculature (Kimberley 2005). Doxil is also approved 
by the FDA for treatment of ovarian cancer and multiple myeloma. Outside the 
United States, Doxil is known as Caelyx and is marketed by Janssen. However, 
the polyethylene glycol coating usually results in a side effect called palmar 
plantar erythrodysesthesia (PPE), more commonly known as hand-foot 
syndrome. The result of the leakage of drugs from capillaries in the palms of the 
hands and soles of the feet after administration of Doxil is redness, tenderness, 
and peeling of the skin that can be painful (Lorusso 2007). The prevalence of 
this side effect limits the Doxil dose and thereby limits potential application. 
Myocet is a non- pegylated liposomal formulation of doxorubicin. Unlike Doxil, 
since Myocet liposome does not has a polyethylene glycol coating, it does not 
result in the same prevalence of hand-foot syndrome, which may allow for its 
substitution for doxorubicin in the same treatment regimen, thereby improving 
safety with no loss of efficacy. 
 
1.5.3. The combination of TNFα with chemotherapy for cancer therapy 
Conventional anticancer strategies are destruction of tumor cells directly by 
surgery, radiotherapy or chemotherapy, while recently indirect attacks of 
tumors by means of agents destroying intratumoral vessels are suggested to be 
efficient, since cancer growth depends on the formation of a vascular supply, 
which is referred to as tumor angiogenesis (Lejeune 2006). It is well recognized 
that the pathophysiology of the tumor vasculature and stromal compartment 
presents an important obstacle which induce inadequate drug delivery leading 
to poor response and regrowth of tumors. Thus, delivery of drugs into solid 
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tumors is still a major problem faced in chemotherapy; adequate levels of 
chemotherapeutics reaching the tumor cells of solid tumors are indispensable 
for a successful chemotherapy. Methods to enhance vascular abnormality, 
such as augmenting leakage of the tumor-associated vasculature, may improve 
tumor response to chemotherapeutics as well. It was believed that recombinant 
humanTNFα has pleiotropic properties; it has strong effects on angiogenic 
vessels in tumors, and the ability to cause apoptosis of tumor-associated 
endothelial cells which leads to the complete destruction of the tumor 
vasculature. In the study of ten Hagen‘s group, they found that that addition of 
TNFα rendered more tumor vessels permeable, thus augmented the tumor 
accumulation of these liposomes 5- to 6-fold, and also induced a more 
homogeneous distribution of the liposomes throughout the tumor, which 
induced strongly enhanced tumor response. It was believed that vasoactive 
drugs like TNFα can augment the vascular leakage, leading to delivery of 
nanoparticulate drug formulations to solid tumor (Seynhaeve 2007). The 
mechanism involved in these events could include the rapid (in the order of 
minutes) perturbation of cell-cell adhesive junctions and inhibition of αvβ3 
integrin signalling in tumor-associated vessels, and the subsequently massive 
death of endothelial cells and tumor vascular collapse 24 hours later 
(Seynhaeve 2007). In addition, in the isolated limb perfusion, addition of TNFα 
results in increased accumulation of drug inside the tumor leading to improved 
response rates (van der Veen 2000; Hoving 2006). Studies on the mechanism 
show that TNF alone was ineffective, however, when combined with melphalan 
chemotherapy in a rat osteosarcoma ILP model together with mild 
hyperthermia, these treatments synergize resulting in a very high objective 
response rate (de Wilt 1999). TNFα treatment leads to an increase in 
endothelium permeability which subsequently facilitates augmented 
accumulation and distribution of the drug in the tumor; besides, killing of 
angiogenic endothelial cells results in tumor vessel destruction. As mention in 
section 1.2.4, the TNFα induced hyperpermeability, along with the dual 
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targeting—the tumor-associated vasculature (TAV ) (by TNF-α) and the tumor 
cells (by the chemotherapy drug)— might explain the observed synergy 
between TNF and chemotherapy in locoregional treatment of patients with 
advanced tumors of the limb (Lienard 1999). 
 
1.6. Existing TNFα gene therapy approaches for cancer therapy 
As mention above, gene therapy which can be used either alone or as an 
adjuvant to other treatment modalities is the emerging modality for the 
treatment of cancer. Exhibit tumor specificity, efficiency and safety are three 
indispensable factors for the development of vectors which can lead to success 
of cancer gene therapy. Particularly attractive for cancer treatment is the 
potential of gene therapy to target the expression of therapeutic genes to the 
desired target cells. Potential to improve local tumor control through the 
delivery of therapeutic DNA constructs that encode cytotoxic or 
immunomodulating proteins have demonstrated in the preclinical gene therapy 
studies (Staba MJ 1998). The pleiotropic cytokine tumor necrosis factor TNFα 
was originally known for its ability to induce hemorrhagic tumor necrosis and 
tumor regression. However, the need to target TNFα activity to the tumor is 
indispensable due to the fact that the therapeutic application of TNFα is 
hampered by its high systemic toxicity (Kircheis R 2003). In the past decades, 
many researchers have put emphasis on employing viral or non-viral gene 
carriers to target delivery TNFα-coding plasmid to the tumor, to express the 
TNFα gene at high levels with minimum toxicity. TNFα gene therapy has been 
applied either alone or as an adjuvant to other treatment modalities such as 
ionizing radiation or chemotherapy. Till now, many related encouraging results 
have been achieved.  
  
1.6.1. Adenoviral TNFα gene therapy 
In the 1990s, scientists from Ralph R. Weichselbaum’s lab in Harvard 
University investigated the interactive effects of adenoviral TNFα gene therapy 
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and radiotherapy in human malignant glioma (D54) xenografts (Staba MJ 1998) 
and human epidermoid carcinoma (SQ-20B) xenografts (Hallahan DE 1995). 
They administered Ad.Egr-TNF, an adenoviral vector (Ad5) which contains 
DNA sequences of the radiation-inducible early growth response gene (Egr-1) 
promoter linking to a cDNA encoding the TNFα gene) and radiation, to both 
human malignant glioma (D54) xenografts (Staba MJ 1998) and human 
epidermoid carcinoma (SQ-20B) xenografts (Hallahan DE 1995) and observed 
significant tumor regression, tumor growth delay, compared with xenografts 
treated with either agent alone or Ad.null with radiation (Hallahan DE 1995; 
Staba MJ 1998). They took advantage of both the killing effect and the targeting 
potential of ionizing radiation to achieve spatial and temporal regulation of 
TNFα gene transcription and enhance tumor cell killing (Hallahan DE 1995). 
In the 2000s, based on these researches, a new drug named TNFerade that 
employs a replication–deficient adenoviral vector carrying the gene for human 
tumor necrosis factor TNFα , regulated by radiation-sensitive promoter , was 
under development by Genvec and has applied in the phase I/ II/III clinical trials 
for the potential treatment of cancer including pancreas cancer, Esophagus 
tumor, sarcoma, solid tumor and so on (Sharma A. 2001; Kircheis R 2003). 
Results of clinical trials demonstrated that most of patients TNFerade treated 
showed objective tumor response (tumor shrinkage) which is dose dependency. 
Meanwhile, TNFerade was well tolerated by patients with mild side effect 
(Sharma A. 2001; Kircheis R 2003), which suggests that it has promising 
potential for development into a new anticancer agent. 
 
1.6.2. Cationic liposomes mediated TNFα gene therapy 
Besides the works of adenovector–mediate TNFα gene therapy, cationic 
liposomes–mediated TNFα gene transfection has been utilized in in vitro and in 
vivo experiments. In 1997, scientists from Dr. Ohno’s lab administered the 
liposome–DNA–HMG-1,2 complex intraperitoneally to tumor bearing nude 
mice and demonstrated the median survival of tumor bearing nude mice was 
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prolonged by the administration of a human tumor necrosis factor-alpha (TNFα) 
gene inserted into a eukaryotic strong expression vector (pcagTNFα) and 
exogenously added interferon- (INF-), compared with groups receiving the 
TNF-α gene inserted in the reverse orientation (pcagTNF-αR) and normal 
saline (NS), pcagTNF-αR and INF-, and pcagTNF-α and NS, respectively 
(Namiki Y 1998). 
. 
1.6.3. Nonviral cationic polymers mediated TNFα gene therapy 
Moreover, many nonviral cationic polymers, such as Transferrin-PEG-PEI was 
employed as gene carrier of TNFα gene and showed the efficient targeting of 
TNFα genes to tumor to reduce side effects like tissue damage (Kircheis R 
2002; Kursa 2003).   
Scientists from our lab found that repeated systemic application of surface - 
shielded Tf–PEI complexes with the tumor necrosis factor (TNFα) gene, or an 
optimum formulation for in vivo application, PEI22/Tf-PEG-PEI/PEI22-PEG5, 
containing plasmid DNA encoding for the TNFα gene, resulted in preferential 
expression of TNFα in the tumor which led to pronounced hemorrhagic tumor 
necrosis and inhibition of tumor growth in three murine tumor models of 
different tissue origins, Neuro2a neuroblastoma, MethA fibrosarcoma, and M-3 
melanoma. No systemic TNFα related toxicity was observed due to the 
localization of the TNF- activity to the tumor (Kircheis R 2002; Kursa 2003). 
In 2009, Christine Dufès‘s lab reported that the intravenous administration of a 
novel delivery system DAB-Tf (transferrin-bearing generation 3- diaminobutyric 
polypropylenimine dendrimer) complexed to a TNFα expression plasmid driven 
by a tumor-specific promoter led to a rapid and sustained tumor regression over 
one month, with long term survival of 90% complete response, 10% partial 
response of the animals (Koppu S. 2010). To sum up, these results might 
suggest that cationic polymer–mediated targeted gene therapy may be an 
attractive strategy applicable to highly active, yet toxic, molecules such as 
TNFα.  
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1.6.4. Preliminary work of TNFα gene therapy combined with liposomal 
doxorubicine for cancer therapy 
Combined gene therapy with chemo- or radiation therapy is one alternative to 
overcome the drawbacks of sigle therapy and to gain a better therapeutic effect 
in cancer treatment; especially when the different molecular actions of genes 
and classical chemotherapeutics or radiation synergize in their therapeutic 
effects. Examples include combination of p53 viral or nonviral gene 
formulations with chemo- (Nemunaitis J 2000; Gautam A 2002) or radiation 
therapy, or TNF gene plus radiation (Hallahan DE 1995; Staba MJ 1998). As 
another example, scientists from our lab have observed enhanced therapeutic 
effects in a murine B16F10 melanoma model by the combination of 
tumor-targeted TNF gene therapy with DOXIL®, a liposomal doxorubicin 
formulation that passively accumulates within tumors (Wagner E. 2004). These 
findings were encouraging, but had preliminary character. Especially the 
applied TNFα plasmid construct were not optimized, leading to suboptimum 
gene expression. There were hopes that the therapeutic strategy can be further 
improved.  
 
1.7. Aim of the thesis 
The aim of this thesis is to combine systemic TNF gene therapy with liposomal 
doxorubicine in the treatment of different tumor models in mice. 
The clinical use of TNF as an anti-cancer drug is limited to local treatments 
because of its dose-limiting systemic toxicity (Curnis 2000). C57B1 mice 
normally tolerated up to 1 x I07U (4.91 µg) per kg TNF i.p. (Jones 1990). The 
problem of its dose-dependent toxicity has been particularly apparent in human 
trials, wherein its maximal tolerated dose was 40 times less than that used in 
mice (Xiang 2003). The maximum tolerated intravenous dose in phase I studies 
was 9 x I05 U (440µg) per m2. Doses at or above 9 x 105 units (400µg ) m2 were 
associated with hypotension, abnormal liver enzymes, leucopenia and mild 
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renal impairment in a substantial proportion of patients (Xiang 2003). Thus, the 
high systemic toxicity induced by recombinant TNFα indicates need to target 
TNFα activity selectively to the tumor. 
Here we want to investigate localized antitumor activity of TNF after systemic 
injection of a non viral, biodegradable gene carrier (G3-HD-OEI) exhibiting 
intrinsic tumor affinity in vivo in murine Neuroblastoma model (Russ 2008). 
Thus, when we employ G3-HD-OEI as gene carrier of optimized TNF coding 
plasmid, it is supposed that most of TNF is expressed in tumor tissue. The 
influrence of pTNF polyplexes application on the accumulation of liposomal 
doxorubicine are evaluated, the pTNF polyplexes are either based on the 
biodegradable polymer G3-HD-OEI in murine neuroblastoma model in A/J mice 
or based on linear polyethylenimine carrying a peptide (GE11) selectively 
binding to the epidermal growth factor receptor (which is highly overexpressed 
in HuH7) (Klutz 2011) in hepatoma xenografts in SCID mice.  
Moreover, a novel TNF coding plasmid with CpG free back bone and hCMV as 
enhancer was cloned and its ability to express TNF is at high and sustained 
levels, since Stephen C Hyde et al observed that CpG-free plasmids with the 
hCMV/EF1α combination confer reduced inflammation and increase the 
magnitude and duration of gene expression in vivo (Hyde 2004). 
Another aim was to investigate any synergistic effects of systemic TNF alpha 
gene therapy together with liposomal doxorubicine in the treatment of 
subcutaneous and metastatic murine neuroblastoma model in A/J mice and 
intrasplenic liver metastatic colon adenocarcinoma model in NMRI-nude mice. 
pTNF containing polyplexes had to be applied using either G3-HD-OEI as gene 
carrier in murine neuroblastoma or LPEI-PEG-GE11 in human hepatocellular 
carcinoma and human colon adenocarcinoma. Results of our studies show that 
combining liposomal chemotherapeutic with TNF gene therapy leads to a 
synergistic effect on tumor reduction in vivo. 
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2. Materials and methods 
2.1. Chemicals, kits, and other materials  
The synthesis of polymers G2-HD-OEI and G3-HD-OEI was described 
previously (Russ 2008). Several grafted polypropylenimine dendrimers were 
synthesized by modifying either polypropylenimine (PPI) dendrimer generation 
2 (G2) or generation 3 (G3) via 1.6-hexandioldiacrylate with branched 
oligoethylenimine 800Da (OEI) or PPI dendrimer G2. LPEI-PEG-GE11 is based 
on linear polyethylenimine carrying a peptide (GE11) selectively binding to the 
epidermal growth factor receptor coupled to LPEI via a heterobifunctional 
polyethyleneglycol linker (2kDa) (Klutz 2011). 
Actinomycin D was purchased from Sigma (Saint Louis, USA) and diluted into 
5mg/ml. Caelyx (liposomal doxorubicin) 2mg/ml is commercially available from 
Schering-Plough (Kenilworth, USA). Corning Transwell polycarbonate 
membrane inserts (pore size 0.4um, membrane diam. 6.5mm were purchased 
from Corning (NY, USA). Mouse TNFα (Tumor Necrosis Factor alpha) ELISA kit 
was purchased from eBioscience (San Diego, CA). 
 
2.2. Cells and animals 
Murine neuroblastoma (Neuro2A, N2A, ATCC CCL-131) and 
Neuro2A-PGK-EGFLuc (Neuro2A lenti Luc cell line transduced with a lentivral 
vector PGK-EGFPLuc for stable luciferase expression, generated by Arzu 
Cengiceroglu (our lab) were cultured with Dulbecco‘s modified Eagle‘s medium 
( DMEM, Biochrom) supplemented with 10% fetal bovine serum, 2 mM of 
L-glutamine. The murine fibroblast cell line L929 (ATCC CCL-1) and U87MG, a 
human glioblastoma-astrocytoma cell line (ATCC HTB 14), were incubated in 
RPMI-1640 (Biochrom) complete medium with 10% fetal bovine serum, 2 mM 
of L-glutamine. Human hepatocellular carcinoma cell line HUH7 (JCRB 0403, 
Tokyo, Japan) was incubated in Ham‘s F-12 complete medium with 10% fetal 
bovine serum, 2 mM of L-glutamine. BT549 , a human breast cancer cell line 
(CLS, #300132) was incubated in RPMI 1640 medium with 0.023 IU/ml insulin, 
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10%; fetal bovine serum. MBA-MD-231, a human breast carcinoma (kindly 
provided by A. Ullrich, Max-Planck Institute, Munich, Germany), was incubated 
in DMEM: Ham's F12 (1:1 mixture) supplemented with 2 mM L-glutamine and 
5% fetal bovine serum. MDA-MB-453 ,a human breast cancer cell line (kindly 
provided by A. Ullrich, Max-Planck Institute, Munich, Germany) was cultivated 
in DMEM/Ham‘s F-12 medium 1:1 supplemented with 10% FCS and 2mM 
stable glutamine and 1% penicillin and streptomycin. Primary porcine 
endothelial cells (PECs) were cultured in M199 medium supplemented with 
10% FCS, and 10ng/ml bFGF (basic fibroblast growth factor) and 100 U/ml of 
penicillin and 100 m g/ml of streptomycin. The human breast adenocarcinoma 
cell line MCF-7 (kindly provided by A. Ullrich, Max-Planck Institute, Munich, 
Germany) was cultured in DMEM medium (5g glucose/l) supplemented with 
20% FCS. Primary porcine smooth muscle cells (PSMC) were isolated by Dr. 
Terese Magnusson according to a protocol by Pelisek et al (Pelisek 2001) and 
grown in Ham s´ F12 (Biochrom, Berlin, Germany)/Waymouth (Gibco, 
Darmstadt, Germany) medium 1:1, 37,5 ‰ sodium bicarbonate (Gibco), 0,01M 
HEPES, 10% bovine calf serum (FCS) (Gibco), 40mM stable glutamine 
(Biochrom), 100U/ml penicillin and 100μg/ml streptomycin (Biochrom), 0,25 
μg/ml amphotericin B (Sigma Aldrich, Steinheim, Germany). PC3 (ATCC 
CRL-1435) human prostate carcinoma was cultured in Eagle's minimal 
essential medium supplemented with 10% FCS. 
LS174T PGK-EGFPLuc (LS174t, human colon adenocarcinoma (ATCC 
CCL188)  transduced with a lentivral vector PGK-EGFPLuc for stable luciferase 
expression, generated by Arzu Cengiceroglu (our lab) were cultured in 
Minimum essential medium (Eagle) in Earle's BSS supplemented with 2 mM 
L-glutamine, 1% non-essential amino acids and 10% fetal bovine serum. All 
cultured cells were grown at 37 °C in 5% CO2 humidified atmosphere. 
A/J mice (6-7 weeks, female) were purchased from Harlan (Bicester, UK). 
NMRI-nude mice (6-7 weeks, female) were purchased from Janvier, France. 
Mice were kept with a 12 h night/day cycle with water and chow provided ad 
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libitum. All animal experiments were approved by the local ethics committee 
and carried out according to the guidelines of the German law of protection of 
animal life. 
 
2.3. Cloning and propagation of plasmids  
Murine TNFα cDNA based on the published sequence (nucleotide ID 
NM_013693.2) was synthesized by Geneart (Regensburg, Germany). The 
sequence was designed for optimized codon usage in mouse, cryptic splicing 
sites were removed. TNFα cDNA was obtained within the vector pMA flanked 
by restriction sites for BglII and NehI. The luciferase gene was excised from 
pCpG-hCMV-Luc plasmid (short: pLuc, details see (Navarro 2010)) by 
BglII-NehI double restriction enzymes digestion and was then ligated with the 
TNFα CDNA excised from the pMA-TNFα plasmid with the same enzymes to 
construct pCpG-hCMV-TNFα (short: pTNF). pdeTNF was constructed by Dr. 
Rudolf Haase (Ludwig-Maximilians-University, Munich) by deleting the EF1a 
promoter of pTNF plasmid, and used as the control plasmid. pRGDTNF, 
encoding the RGD-TNF protein , was obtained by fusing the TNF sequence to 
the C terminus of peptides able to target tumor vessels-----ACDCRGDCFCG, 
which containing Arg-Gly-Asp (RGD) motifs, the detail methods could refer to 
Zarovni‘s paper (Zarovni Apr. 2004), briefly, sequence encoding 
ACDCRGDCFCG was inserted, by polymerase chain reaction (PCR), 
upstream of the mature TNF-coding region, to generate pRGD-TNF. The 
strategy for obtaining pRGD-TNF included two PCRs, aimed at generating two 
overlapping fragments containing complementary parts of the 
ACDCRGDCFCG sequence and the SacII restriction site were generated by 
PCR, using the following primers:  
5-primer-1: TTGAATTCAGACACCATGAGCACAGAAAGC combined with 
3-primer-1a:CGCCCGCGGCAATCGCATGCTGTGAGGGTCTGGGCCATAG
AAA, and 5-primer-2a 
GCCCCGCGGTGATTGCTTCTGTGGCCTCAGATCATCTTCTCAAAATT  
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Combined with 3-primer-2: GGATCCTCACAGAGCAATGACTCCAAAG. 
In view of the natural function of microRNA, pTNF-mir143 was constructed by 
Dr. Rudolf Haase (our lab) by inserting miR-143 targeting sequence (5 copies of 
sequence GAGCTACAGTGCTTCATCTCA) synthesized by Geneart 
(Regensburg, Germany) into plasmid pTNF (at 3' untranslated region of gene 
TNF), thus, the expression of the therapeutic gene should be selectively turned 
off in cells which are enrich in miR-143 through microRNA specifically 
repression, while do not affect the transgene expession in the tissue which are 
low miR-143, such as various cancer cells. All plasmids were amplified in E. coli 
DB3.1λpir, and isolated using a Qiagen (Hilden, Germany) Plasmid Giga or 
Maxi Prep. 
 
2.4. In vitro studies  
2.4.1. Preparation of transfection polyplexes 
DNA polyplexes were prepared as described (Kircheis R. 2001; Kircheis R 2002). 
In vitro, plasmid DNA (40 µg/mL) was flash-mixed with G3-HD-OEI or 
G2-HD-OEI at c/p=1, or with LPEI-PEG-GE11 at c/p=0.78. For in vivo 
application, 125 µl plasmid DNA of concentration 400 µg/ml (to final dose 50 µg 
DNA/mouse) was flash-mixed with 125 µl related polymer at certain c/p ratio 
respectively. Complexes were prepared in 20 mM HEPES (pH=7.4) /5% 
glucose.  
 
2.4.2. In vitro transfection in the Neuro2A cell 
Neuro2A cell was seeded at 7 ×104 cells/well in 24-well tissue culture plates, 
cultured overnight at 37°C and then transfected with G3-HD-OEI/ DNA 
polyplexes (1ug pDNA per well). Four hours after transfection, the medium 
were replaced with the fresh one. Then, from 24 hours till 6 days thereafter, the 
conditioned medium was collected for the L929 cytotoxicity bioassay and 
ELISA and replaced it with the fresh one every 24 hours.  
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2.4.3. TNFα cytotoxicity bioassay 
TNFα cytotoxicity was analyzed by modifying the methods from Ming-Yuh 
Shiau (Shiau 2001). Briefly, 1.25×104 cells/well of L929 cells were seeded in a 
96-well tissue culture plate and were cultured overnight at 37°C. The medium 
was replaced by 100 µl of the conditioned medium of Neuro2A transfected with 
pTNF/G3-HD-OEI which was collected at different time points as described 
above. After L929 cells were exposed in the conditioned medium with 1µg/ml 
actinomycin D for 24h, 10 u l of 5mg/ml MTT was added into each well of L929 
cells. After 4 h of incubation at 37°C, the supernatants in the wells were 
carefully discarded and 100 µl/well of dimethylsulfoxide (DMSO) was added 
into the plate to dissolve Formazan crystals for 10min. The absorbance was 
read and recorded at 570 nm, with reference absorbance at 630nm in the 
microplate reader. Results were represented as the percentage of L929 
cytotoxicity. The percentage of L929 cytotoxicity was calculated by following 
formula: cytotoxicity = (absorbance of 100% viable cell control wells 
–absorbance of test wells) divided absorbance of 100% viable cell control wells.  
 
2.4.4. Endothelial permeability (transwell assay) 
As method mentioned in other papers (BRETT 1989; Nooteboom 2002), we 
seeded PEC at 20,000 per well in the inner chamber of the transwell (coated 
with collagen A), and waited about 72 hours for the confluence of cells. Then, 
the medium in the inner chamber was exchanged for medium containing TNF 
protein (1ng/ml) or conditioned medium from Neuro2A cells transfected with 
G3-HD-OEI/pTNF polyplexes or G3-HD-OEI/pLuc polyplexes (as control), 
together with 1µg/ml actinomycin D. After incubation for another 24 hours, 
FITC-dextran (MW=40,000, Sigma) was added to a final concentration of 
1mg/ml in the inner chamber. 50 min later, the medium in both chambers were 
collected and the fluorescence of dextran were measured in a Cary Eclipse 
fluorescence spectrometer (Lexington, USA) at Ex=490nm, Em=530nm and 
compared with a standard curve prepared with known concentration of 
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FITC-dextran diluted in medium. The percent of transfer was calculated as 
amount of FITC-dextran in outer chamber divide amount of total dextran 
applied in the inner chamber. 
 
2.5. In vivo studies  
2.5.1. Evaluation of luciferase reporter gene expression after systemic 
application 
On day 0 (8 days after subcutaneous inoculation of 1×106 Neuro2A tumor cells,, 
when tumors reached 5-8 mm in size), day 3 and day 6 respectively, 
pLuc/G3-HD-OEI polyplexes at c/p=1 (50µg DNA/ mouse) were intravenously 
injected into A/J mice bearing subcutaneous Neuro2A tumors. 
Bioluminescence imaging (BLI) was carried out under a CCD camera (Xenogen 
IVIS) 10 minutes after intraperitoneal injection of 100 µl luciferin (60 mg/ml) 
every 24 hours. And luciferase activity was quantified in the tumor area by 
Bioluminescence imaging (BLI) and expressed as photons/second/region of 
interest (ROI) (n=3 + stddev). Mice were kept anaesthetised by inhalation of 
isoflurane (Forene, Abbott, Wiebaden-Delkenheim, Germany) by a gas 
manifold with a flow rate of 2% during live Bioluminescence imaging (BLI).  
Two days after last polyplexes injection, mice were sacrificed and organs were 
resected and homogenized with homogenizer (Ultra-turrax 8, Germany) in 1× 
cell lysis buffer (Promega, Mannheim, Germany) The bioluminescence in 
supernatant of organs lysate was measured in a tube luminometer (Lumat LB 
9507, Berthold Technologies, Bad Wildbad, Germany) with an integration time 
of 30 seconds following a 2 seconds lag time after the injection of luciferase 
assay reagent (LAR; 20mM glycylglycine, 1 mM MgCl2, 0,1mM EDTA, 3mM 
DTT (Sigma-Aldrich), 0,55mM ATP (Roche, Mannheim, Germany), 0,3mM CoA 
(Sigma-Aldrich), 0,5 mM dluciferin (Promega), pH 8,5).  
 
2.5.2. Assessment of Caelyx uptake and in tumor and tissue distribution   
Mice were injected intravenously with pTNF/G3-HD-OEI polyplexes or 
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pLuc/G3-HD-OEI polyplexes at c/p=1. 48 hours after polyplexes treatment, 
Caelyx (2 mg/ml) was applied intravenously at a dose of 100 µg/ mouse (diluted 
in 250 µl PBS buffer). 24 hours after Caelyx application, at which time maximal 
tumor localization by Stealth liposomes is expected (van der Veen 1998; HAGEN 
2000), mice were sacrificed and the tumors and other organs excised and 
weighted. Tumors were analyzed for Caelyx and its fluorescent metabolites as 
described (Mayer 1989; HAGEN 2000). Briefly, after incubation of tissue in 
acidified isopropanol (0.075 N HCl in 90% isopropanol) for 24 hours at 4°C, 
tumors and indicated organs were homogenized (using an IKA Homogenizer), 
centrifuged for 30 min at 4000 rpm and supernatants were harvested. Samples 
were measured in a Cary Eclipse fluorescence spectrometer (Lexington, USA) 
at excitation 480 nm and emission 590 nm and compared with a standard curve 
prepared with known concentration of Caelyx diluted in acidified isopropanol.  
 
2.5.3. Evaluation of Caelyx-DiR accumulation by living image 
Caelyx  liposomes were labeled with 
1,1‘-dioctadecyl-3,3,3‘,3‘-tetramethylindotricarbocyanine iodide (DiR) by 
incubation with 0.2 mol% of the lipophilic tracer DiR (Molecular Probes) for 
15min at room temperature (Seynhaeve 2007). Mice were injected 
intravenously with pTNF/G3-HD-OEI polyplexes or pLuc/G3-HD-OEI 
polyplexes at c/p=1. 48 hours after polyplexes treatment, Caelyx-DiR was 
applied i.v. at a dose of 5mg/kg. From immediately after injection until 15 
minutes after application, mice were imaged in the IVIS imager with aCCD 
camera using the ICG filter set (Xenogen Ivis), and the signal of fluorescence in 
tumor tissue was measured. At 24 hours after treatment, mice were imaged 
again. Mice were kept anaesthetised by inhalation of isoflurane (Forene, Abbott, 
Wiebaden-Delkenheim, Germany) by a gas manifold with a flow rate of 2% 
during live imaging. At 72 hours after treatment, mice were sacrificed, organs 
were resected and imaged in vitro.  
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2.5.4. Application of pTNF/G3-HD-OEI polyplexes in the subcutaneous 
murine neuroblastoma model  
On day 0 (8 days after 1×106 Neuro2A tumor cells suspending in 100 µl PBS 
subcutaneous inoculation, when tumors reached 5-8 mm in size), day 3 and 
day 6 respectively, pTNF/G3-HD-OEI polyplexes or pLuc/G3-HD-OEI 
polyplexes at c/p=1 (prepared as above described, 50µg DNA/ mouse) were 
intravenously injected every third days into A/J mice (n=6) bearing 
subcutaneous Neuro2A tumors. The tumor size and body weight of the animals 
were monitored. Differences in tumor growth were statistically analyzed by 
T-TEST. 
 
2.5.5. Application of pTNF/G3-HD-OEI polyplexes and Caelyx in the 
subcutaneous murine neuroblastoma model  
At 10 days after neuroblastoma subcutaneous inoculated, A/J mice (n=12) 
were intravenously injected with pTNF /G3-HD-OEI polyplexes or 
pLuc/G3-HD-OEI polyplexes every forth days for three cycles, and every 
second days after polyplexes application, Caelyx was applied at a dose of 
1.5mg/kg (30 μg diluted in 250 μl PBS per mouse). The tumor size and body 
weight were monitored every two days. Differences in tumor growth were 
statistically analyzed. In the retreated (or boost) model, an additional treatment 
cycle 6 days after last treatment was conducted with 7 out total 11 mice in the 
group, and the tumor size was monitored continuously.  
 
2.5.6. Application of pTNF/G3-HD-OEI polyplexes and Caelyx in the 
metastatic murine neuroblastoma model 
At day 6 after intravenous inoculation of 1×106 Neuro2A lenti Luc cells in 200 μl 
PBS, mice were intravenously injected with pTNF/G3-HD-OEI polyplexes or 
pdeTNF/G3-HD-OEI polyplexes (plasmid without promoter, used as control) 
every forth days for three times totally, and every second days after polyplexes 
application, Caelyx was applied at 1.5mg/kg (n=10). Bioluminescence imaging 
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(BLI) was carried out (ventral, dorsal and lateral side of mice) after 
intraperitoneal injection of luciferin. Mice were kept anaesthetised by inhalation 
of isoflurane (Forene, Abbott, Wiebaden-Delkenheim., Germany) by a gas 
manifold with a flow rate of 2% during live Bioluminescence imaging (BLI). 
Luciferase activity was quantified in the tumor area by BLI and expressed as 
photons/second/region of interest (ROI). At 6 days after last treatment, mice 
were sacrificed, and tumor metastases in the body cavity were observed and 
pictures taken by camera. Bowels (including heart, lung, liver, spleen, kidney, 
small and large intestine) were taken out and weighted, and the weight of 
tumors was calculated by deducting the average weight of visceral of mice 
(n=3+) without tumor cell inoculation but with the same treatment of polyplexes 
and Caelyx. The organs and tumor tissues of mice were either fixed in formalin 
for HE staining or stored in Tissue Freezing Medium at -80 °C for further 
cryosectioning. The experiment was performed twice independently. 
 
2.5.7. Establishment of the LS 174t lenti Luc cell line in an intrasplenic 
liver metastasis model 
The procedure has been carried out by Katarina Farklasova (veterinarian) and 
is described in detail in her PhD thesis. In brief, NMRI-nude mice (n = 34) were 
injected with 7,5x105 LS174t lenti Luc cells into the spleen. For tumor injection 
the mice were anaesthetized by inhalation of isoflurane in oxygen (2.5% (v/v)) 
at a flow of 1 liter/min. Bepanthene® was put on the eyes to protect them. 
Rimadyl® (5mg/kg) was injected subcutaneously prior to tumor injection. The 
mouse was positioned on the right lateral side. The skin was first swabbed with 
ethanol, after it evaporated, the skin was swabbed with braunol®. The skin was 
raised and a vertical cut (ca. 0,5cm) throw the skin caudal to the costal arch was 
made. The muscle-layer and the peritoneum were raised and another vertical 
cut (ca. 0,5cm) was made to open the abdominal cavity. The lower part of the 
spleen was partially displaced out of the abdomen and the cell suspension was 
slowly injected using a 27G needle. Using a cotton swab, gentle pressure was 
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made on the injection site to prevent cell reflux throw the injection channel and 
bleeding. The spleen was placed back to the abdomen. The peritoneum and 
the muscle were sutured in one layer and the skin in another layer using 
Monosyn® 5/0. The mice were separately put into cages with gloves filled with 
hot water to keep them warm and to recover undisturbed from the other mice 
from surgery. 24 and 48 hours after tumor injection the mice were injected 
subcutaneously 5mg/kg Rimadyl® (Katarina Farkasova 's phD Thesis 2011).  
 
2.5.8. Application of pTNF/ LPEI-PEG-GE11 polyplexes and Caelyx in the 
metastatic colon adenocarcinoma model 
At 3 days after the inoculation of the cells, mice were intravenously injected with 
pTNF /LPEI-PEG-GE11I polyplexes or pdeTNF/LPEI-PEG-GE11 polyplexes 
(plasmid without promoter, used as control) every third day for three times 
totally, and every second days after polyplexes application, Caelyx was applied 
at 1.5mg/kg. Bioluminescence imaging (BLI) was carried out from abdominal 
side of mice after intraperitoneal injection of luciferin. Luciferase activity was 
quantified in the tumor area by BLI and expressed as photons/second/region of 
interest (ROI) (n=11). Mice were kept anaesthetised by inhalation of isoflurane 
(Forene, Abbott, Wiebaden-Delkenheim, Germany) by a gas manifold with a 
flow rate of 2% during live Bioluminescence imaging (BLI). At 12 days after cells 
inoculation, mice were sacrificed, and tumor metastases in the viscral were 
observed and pictures were taken by camera. The livers and spleens of mice 
were taken out and weighted, a liver lobe fixed in formalin for HE staining and 
the residual liver and spleen were frozen at -80°C. Frozen livers were grinded to 
powder with liquid nitrogen which were then lysed with1× cell lysis reagent 
(Promega, Mannheim, Germany). The concentration of total protein in 
supernatant of liver lysate was measured with the kit of Pierce BCA Protein 
Assay (Thermo Scientific) and the bioluminescence signal was measured in a 
tube luminometer (Lumat LB 9507, Berthold Technologies, Bad Wildbad, 
Germany) with an integration time of 30 seconds following a 2 seconds lag time 
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after the injection of luciferase assay reagent (LAR; 20mM glycylglycine, 1 mM 
MgCl2, 0,1mM EDTA, 3mM DTT (Sigma-Aldrich), 0,55mM ATP (Roche, 
Mannheim, Germany), 0,3mM CoA (Sigma-Aldrich), 0,5 mM Dluciferin 
(Promega), pH 8,5). And the results expressed as relative light units (RLU) per 
µg total protein. 
 
2.6. Evaluation of TNF gene expression in tumors and livers by qPCR 
The high pure RNA Tissue Kit (Roche, Switzerland) was used for the isolation 
of total RNA from tumor and liver. cDNA was obtained by using the high fidelity 
transcriptor cDNA synthesis kit. The qPCR assay was handled using light 
cycler 480 probes Master buffer in the Roche Light Cycler 480 qPCR machine 
(Basel, Switzerland). The expression of TNF and of the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in tumor and liver was 
determined in parallel from the same reverse transcriptase reaction, each done 
in duplicate per sample. The primer used for TNF gene: forward primer: 
GCTTCCAGAACAGCAGACG; reverse primer: AGGCAGAACAGGGTGGTG; 
the primer for the GAPDH gene:  
forword primer:AGCTTGTCATCAACGGGAAG; reverse 
primer:TTTGATGTTAGTGGGGTCTCG. The untreated sample was used as 
calibrator cDNA. Since the murine TNF cDNA sequence of pTNF was 
synthesized for optimal codon usage in mice and hence different to the 
wild-type TNF sequence is was possible to determine mRNA levels of 
transgenic TNF in tumor and liver by qPCR. By blasting the standard TNF with 
our codon optimal TNF sequences, the least similarity places were found out 
and designed the primers, then the primers were evaluated by normal PCR to 
prove that they can only amplify transgenic TNF in pTNF/G3-HD-OEI 
polyplexes treated samples, whereas wild type TNF is not amplified. The primer 
of transgenic TNF gene: forward primer: AAGCTCTAGCCAGAATAGCTCC; 
reverse primer: ACAGCCACTCCAGCTGCT;  
Here we used liver cDNA as calibrator cDNA. At 48 hours after 
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pTNF/G3-HD-OEI polyplexes were intravenously injected into A/J mice bearing 
subcutaneous Neuro2A tumors, mice (n=3+ stddev) were sacrificed and tumor 
and liver tissue were collected. TNF expression in tumor tissue was determined 
at mRNA level by RT-qPCR and was normalized to the expression of the 
GAPDH housekeeping gene. All samples were done in duplicates. Relative 
transgenic TNF mRNA in tumor tissue of pTNF treated group was also 
determined at mRNA level by RT-qPCR and was normalized to the expression 
of TNF mRNA in liver tissue. 
 
2.7. Immunohistological stain  
2.7.1. Immunostaining with anti-CD31  
One week after Neuro2A cell inoculation, mice were treated with 
pTNF/G3-HD-OEI polyplexes or pLuc/G3-HD-OEI polyplexes every third day 
for three times totally, at the third days after the last injection mice were 
sacrificed and tumors were resected. Tumor cryosections (5μm) on microslides 
were fixed in cold methanol for 5 min, and were blocked with 1% BSA for 15 
minutes, with 10% goat serum for 15 minutes, and subsequently incubated with 
rat anti murine CD31 mAb (CD31: endothelial marker) (eBioscience San Diego, 
CA) for 2 hours, thereafter washed twice with 1%BSA/PBS, the slide was 
stained with Alexa Fluor 647 goat anti-rat IgG for 1hour and also washed twice 
with PBS. Then the slides were incubated with 0.5µg/ml DAPI for 10 min to 
stain nuclei with DAPI (blue), and then washed three times with water and 
mounted with Vectashield mounting media (Burlingame, USA) after drying 
under dark. The slides were evaluated with a Zeiss Axiovert 200 microscope 
(Carl Zeiss, Jena, Germany).    
 
2.7.2. Immunostaining with anti-TNF  
At 6 days after intravenous inoculation of Neuro2A lenti Luc cells, mice were 
treated with pTNF/G3-HD-OEI polyplexes or pdeTNF/G3-HD-OEI polyplexes 
every forth days for three times totally, and every second days after polyplexes 
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application Caelyx was applied at a dose of 1.5mg/kg. At 22 days after tumor 
cell inoculation, mice were sacrificed and dissected, the tumor tissue collected 
and embedded in Sakura Tissue Tek in Cryomolds and stored at -80°C. Tumor 
cryosections (5μm) on microslides were fixed in cold methanol for 5 min, and 
were blocked with 1% BSA for 15 minutes, with 10% goat serum for 15 minutes, 
and subsequently incubated with rabbit anti-mouse TNF- α antibody (abcam 
ab9739) for 2 hours and then washed twice with 1%BSA/PBS. The slides were 
incubated with Alexa Fluor 488 labeled goat-anti- rabbit secondary antibody 
(invitrogen) for 1 hour followed by two washing steps with PBS. Then the slides 
were incubated with 0.5µg/ml DAPI for 10 min to counterstained nuclei and then 
washed three times with water. After mounting with Vectashield mounting 
media (Burlingame, USA), the slides were evaluated under Zeiss Axiovert 200 
microscope (Carl Zeiss, Jena, Germany) with 20x objective magnification.  
 
2.7.3. Preparation cryosection slices 
For the cryosection of tissue in the Caelyx treatment experiment, 48h after a 
single pTNF/ G3-HD-OEI polyplex in Neuroblastoma bearing mice, 5 mg/kg 
Caelyx were injected intravenously. 24 hours later, tumor and liver tissues were 
collected and the cryosections (5μm) on microslides were fixed in cold 
methanol for 5 min and mounted with Vectasheld mounting media after drying 
under dark and observed under Zeiss Axiovert 200 microscope (Carl Zeiss, 
Jena, Germany) with 20x objective magnification.  
 
2.7.4. HE Staining 
After sacrificing the mice, the organs were collected and fixed in formalin 
solution (4%) overnight. After two hours of washing in running water to remove 
formalin residues, the organs were stored in ethanol (70%). Then, the tissues 
were handled with tissue processor machine and slices (5µm of thickness) 
were cut with a LEICA RM2265 rotary microtome and transferred to 
glass-slides. For the staining, slides were de-waxed in two identical xylole 
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solutions (>98%, Roth) for 15min each. This step was followed by an alcohol 
dilution series (ethanol: 100%, 96%, 70%), washing the slides once in each 
dilution for 5min. After a short washing step with purified water, the slides were 
treated in Mayers- Haemalaun (Merck) for 1 min to stain the nuclei, and washed 
in running water again for 10 minutes. For cytoplasm staining, the slides were 
covered in eosin (2%, Chroma) for 8 min. Again, the slides were washed in 
running water for 3 min and then treated with the alcohol dilution series in 
reversed order (70% for 3min, 96% for 3min, 100% for 5min). At last, the slides 
were dewatered by using the xylole solutions twice, 10 min each. After 
evaporation of solvent residues, the slices were sealed with Eukitt (O.Kindler 
GmbH&Co) and a glass-cover. Then, slides were evaluated with a Zeiss 
Axiovert 200 microscope (Carl Zeiss, Jena, Germany) with 10x or 20x objective 
magnification. The obtained pictures were processed, using Adobe Photoshop 
CS5 for adjusting color and contrast adjustments and adding a scale bar and 
merging single pictures into bigger ones. 
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3. Results 
3.1. Evaluation of plasmid pTNF transgene expression in vitro  
We used a novel plasmid vector with CpG free backbone and an optimized 
promoter-enhancer combination (human CMV enhancer and EF1α promoter), 
since as mention in section 1.7., Stephen C Hyde et al observed that CpG-free 
plasmids with the hCMV/EF1α combination confer reduced inflammation and 
increase the magnitude and duration of gene expression in vivo (Hyde 2004). 
To evaluate the expression efficiency of the TNF coding plasmid pTNF, the 
L929 Bioassay was applied. L929, a murine aneuploid fibrosarcoma cell line, is 
used to assay TNF-alpha and TNF-beta, which lyse cells sensitized by 
pretreatment with actinomycin or cycloheximide. Treatment with TNF initiates 
apoptosis and subsequent cell death. We transfected Neuro2A cells with pTNF 
/G3-HD-OEI polyplexes or control polyplexes. In addition, polyplexes were 
formed with the plasmid pGSmuTNF (Kircheis R 2002), which contains a CMV 
driven expression cassette and a standard, CpG rich backbone. Collected the 
supernatant every 24 hours and changed for fresh medium. 24 hours after 
adding the condition medium from treated Neuro2A to L929 cell, the cytotoxicity 
caused by TNF was detected by MTT method. We found that the novel plasmid 
vector with CpG free backbone and an optimized promoter-enhancer 
combination led to sustained and high TNF transgene expression in vitro on 
Neuro2A murine neuroblastoma cells. Secreted TNF induced high cytotoxicity 
on L929 indicator cells and its expression in Neuro2A cells lasted for at least 
one week (fig. 1 A). As further evidence, an ELISA assay was also performed 
to detect the concentration of secreted TNF in conditioned medium and lysate 
of transfected cells. Clearly, the novel plasmid vector with CpG free backbone 
and an optimized promoter-enhancer combination led to sustained and high 
TNF transgene expression in vitro on Neuro2A murine neuroblastoma cells with 
up to 600 pg protein/mL/24h peaking between 48h and 72h after transfection in 
condition medium (fig. 1 B) and high amounts of TNF were also found in pTNF 
polyplex transfected Neuro2A cells (fig. 1 C). These results suggest that the 
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novel plasmid vector with CpG free backbone and an optimized 
promoter-enhancer combination is definitely powerful at inducing sustained and 
high transgene expression being far more efficient when compared to the CMV 
driven plasmid pGSmuTNF. 
 
Fig. 1 A  
  
Fig. 1 B 
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Fig. 1 C 
Fig. 1:  Evaluation plasmid pTNF transgene expression in vitro 
A, Neuro2A cells were transfected with pTNF/G3-HD-OEI, pGSmuTNF/G3-HD-OEI or 
pLuc/G3-HD-OEI polyplexes respectively, and the supernatant were collected and 
changed freshly every 24h. Bioactivities of soluble TNF in the condition medium were 
detected by L929 indicator cell bioassay. B, C, the concentrations of TNF in both condition 
medium and lysate solution of transfected cells were measured by ELISA. 
 
3.2. Evaluation the influence of pTNF plolyplexes on endothelial cell 
permeability in a transwell system  
To find out the effect of pTNF polyplexes treatment on endothelial cell, a 
transwell experiment was performed. Fig. 2 A showed the schematic trans-well 
system. We found that secreted TNF in the conditioned medium from Neuro2A 
cells transfected with pTNF/ G3-HD-OEI polyplexes combined with actinomycin 
D increased endothelial cell permeability in a trans-well system, and was 
comparable with the effect induced by TNF protein at final concentration 1ng/ml 
(fig. 2 B), while there was no significant transfer of FITC- Dextran detected 
induced by the conditioned medium from Neuro2A cells transfected with 
pLuc/G3-HD-OEI polyplexes combined with actinomycin D. These results 
might due to the secreted TNF in the condition medium induced by pTNF 
polyplexes transfection leading to the apoptosis of PEC and/or enlargement of 
the cell gaps which facilitated the pass through of dextran-FITC. This is 
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consistent with other papers which declared that TNF induce the major 
destruction of the vascular bed (Nawroth 1986; Palladino 1987; Nawroth 1988; 
Clauss 1990; Gasparri 1999). However, when we transfected the cell lines 
Neuro2A, HuH7, U87MG, BT549, MBA-MD-231,MBA-MD-453 or L929 with 
pTNF/G3-HD-OEI or pLuc/G3-HD-OEI polyplexes and measured the 
cytotoxicity caused by secreted TNF directly, we found that TNF did not exert 
direct tumor cell toxicity on HUH7, Neuro2A, U87MG and MBA-MD-231 cells 
while moderate toxicity was found on MBA-MD-453 and BT549 cells ( fig. 2 C ). 
L929 murine fibroblasts were used as positive control, as significant reduction 
in cell viability is seen on L929 (the same as used in L929 bioassay in fig. 1 A). 
             Fig. 2 
A 
 
Fig. 2 B 
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Fig. 2 C 
Fig. 2: Evaluation the influerence of pTNF/G3-HD-OEI plolyplexes on endothelial cell 
permeability in a trans-well system    
A, Schematic trans-well system. B, PEC were seeded at 20,000 per well in the inner 
chamber of the transwell (coated with collagen A), and grew for about 72 hours until 
confluence of cells. Then, the medium in the inner chamber was exchanged for medium 
containing TNF protein (1ng/ml) or conditioned medium from Neuro2A cells transfected 
with G3-HD-OEI/pTNF polyplexes or G3-HD-OEI/pLuc polyplexes (as control), together 
with 1µg/ml actinomycin D. FITC-dextran (MW=40,000, Sigma) was added to a final 
concentration of 1mg/ml in the inner chamber.  50 min later, the medium in both chambers 
was collected, the fluorescence of dextran measured in a Cary Eclipse fluorescence 
spectrometer (Lexington, USA) at Ex=490nm, Em=530nm and compared with a standard 
curve prepared with known concentration of FITC-dextran diluted in medium. The percent 
of transfer was calculated as amount of FITC-dextran in outer chamber divide amount of 
total dextran applied in the inner chamber. The percent of transfer was calculated as the 
percent of amount of FITC-dextran in outer chamber divided amount of total dextran 
applied. C, 24h after Neuro2A, HuH7, U87MG, BT549, MBA-MD-231, MBA-MD-453 or 
L929 cell lines were seeded, the cells were transfected with pTNF/G3-HD-OEI or 
pLuc/G3-HD-OEI polyplexes and 24h later the cytotoxicity was measured by MTT assay. 
 
3.3. Evaluation TNF targeting expression plasmid pRGD-TNF or selective 
expression plasmid pTNF-miR143 
As mention in section 1.2.4., the antitumor activity of TNF depends on indirect 
mechanisms associated with selective destruction of the tumor-associated 
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vascular bed, which provide the rationale for developing vasculature-targeting 
strategies aimed at increasing the therapeutic index of this cytokine. As 
mention in section 1.3.2, several peptides such as CNGRC and CDCRGDCFC, 
containing Asn-Gly-Arg (NGR) or Arg-Gly-Asp (RGD) motifs, have been used 
for targeting chemotherapeutic drugs, proapoptotic peptides, and cytokines to 
tumors in experimental models (Arap 1998; Zarovni 2004). Thus, similar as 
Natasa Zarovni and some other scientists did (Zarovni Apr. 2004), here we try 
to employ the RGD motif in our pTNF plasmid to target transgenic TNF as a 
RGD-TNF fusion to the endothelium. To construct the pRGD-TNF plasmids, 
sequence encoding ACDCRGDCFCG was inserted by polymerase chain 
reaction (PCR) upstream of the mature TNF-coding region. To evaluate the 
expression efficiency of the pRGD-TNF plasmid, L929 Bioassay was performed. 
Compared with pTNF plasmid, the plasmid containing vasculature-targeting 
peptide RGD gene fused with mature TNF gene, pRGD-TNF, induced 
expression and secretion of RGD-TNF into the medium which led to higher 
cytotoxicity on L929 indicator cell (fig. 3 A). This could be because the 
transgenic RGD peptide targeted the intergrinα5 on the surface of L929 cell, 
which further promoted internalization and subsequently induced higher 
cytotoxicity on L929 indicator cells. In order to investigate the therapeutic 
potential of pRGD-TNF and compare with pTNF plasmid in vivo, we applied the 
pRGD-TNF/ G3-HD-OEI or pTNF/G3-HD-OEI polyplexes in the murine 
neuroblastoma model and measured the tumor size continuously. We found 
that three rounds pRGD-TNF polyplexes intravenous application led to 
inhibition of tumor growth in mice; however, the inhibition effect was only 
moderately enhanced when compared to pTNF polyplex treatment (fig. 3 B). 
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Fig. 3 A, B: Evaluation of TNF targeting expression plasmid pRGD-TNF   
A, 24 hours after Neuro2A cells were seeded, the cells were transfected with 
pTNF/G3-HD-OEI, pRGD-TNF/G3-HD-OEI or pLuc/G3-HD-OEI polyplexes and 24h later, 
the condition medium were collected. Bioactivities of soluble TNF in the condition medium 
were detected by L929 indicator cell bioassay. B, Eight days after Neuro 2A cell inoculation, 
mice were treated with pTNF/G3-HD-OEI, pRGD-TNF/G3-HD-OEI or pLuc/G3-HD-OEI 
polyplexes every third day, and the tumor size was measured coutinuously (n= 6). 
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As mention in section 1.3.3., in view of the natural function of microRNA and 
the specific abundance of miR-143 in different tissues, here pTNF-mir143 was 
constructed by inserting miR-143 targeting sequence into plasmid pTNF. To 
detect the influence of miR-143 on the TNF transgene expression in different 
cell line, we transfected PSMC (Primary porcine smooth muscle cells, high in 
miR-143, investigated by Florian Kopp and Maria Schnödt, unpublished results) 
and PC3 cells (human prostate carcinoma, low in miR-143, investigated by 
Florian Kopp and Maria Schnödt, unpublished results) with 
pTNF-miR143/G3-HD-OEI and pTNF /G3-HD-OEI polyplexes as control. 
Secreted TNF in condition medium were detected by L929 bioassay. The 
results of the bioassay proved that transgene expression of TNF induced by the 
plasmid containing miR-143 targeting sequence (pTNF-miR-143) is 
significantly down- regulated in PSMC while no influence is found in PC3 cells 
( fig. 3 C ). However, when we transfected another cancer cell line, Neuro2A 
(murine neuroblastoma), with pTNF-miR143 /G3-HD-OEI polyplexes, as the 
result of bioassay shown, the expression of TNF induced by the pTNF-miR143 
/G3-HD-OEI polyplexes was also decreased (fig. 3 D), which might suggest 
that not all tumor cell line exhibit a low miR-143 level.    
 
Fig. 3 C 
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Fig. 3 C,D:  Evaluation TNF selective expression plasmid pTNF-miR143   
24 hours after PSMC or PC3 (C) and Neuro2A cells (D) were seeded, the cells were 
transfected with pTNF/G3-HD-OEI or pTNF-mir143/G3-HD-OEI polyplexes and 24h later 
the condition medium was collected. Bioactivities of soluble TNF in the condition medium 
were detected by L929 indicator cell bioassay. 
 
3.4. Evaluation of G3-HD-OEI as gene carrier of luciferase reporter gene 
in vivo after systemic application 
As mention in section 1.4.3., several grafted polypropylenimine dendrimers 
were synthesized by Dr. Verena Russ in our lab through modifying either 
polypropylenimine (PPI) dendrimer generation 2 (G2) or generation 3 (G3) via 
1.6-hexandioldiacrylate with oligoamines, like branched oligoethylenimine 
800Da (OEI) or PPI dendrimer G2 (Russ Dec 2008). In vitro results showed that 
transfection levels obtained with OEI-grafted dendrimers were the highest, 
being similar or even higher as compared to standard polyethylenimines (linear 
and branched). Here, these polymers were evaluated for transfecting 
subcutaneous Neuro2A tumors after repeated systemic polyplex application 
with pLuc (luciferase encoding plasmid) containing polyplexes. After tail vein 
injections of G3-HD-OEI/pLuc  polyplexes into mice bearing subcutaneous 
Neuro2A tumors, BLI imaging was performed every 24h and showed that the 
tumor targeting transgenic expression of luciferase could be detected for at 
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least one week in G3-HD-OEI/pLuc polyplexes treated mice (fig. 4 A). As 
quantification results of the photon strength also showed, transgenic activity of 
polyplexes in tumor tissue remained high for at least one week (fig. 4 B). When 
organs of mice were resected and homogenized, bioluminescence was 
measured in the supernatant of organs lysate. The same trends were found, 
that the transgenic expression in tumor tissue is significant higher than in other 
organs (fig. 4 C). This again shows that G3-HD-OEI, a non viral, biodegradable 
gene carrier (G3-HD-OEI) exhibits intrinsic tumor affinity. 
      
Fig. 4 A 
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Fig. 4 C 
Fig. 4: Evaluation of G3-HD-OEI as gene carrier of luciferase reporter gene in vivo 
after systemic application   
pLuc/G3-HD-OEI polyplexes were intravenously injected every third days into A/J mice 
bearing subcutaneous Neuro2A tumors. A, Bioluminescence imaging (BLI) was carried out 
in the IVIS imager with a CCD camera (Xenogen Ivis) after intraperitoneal injection of 
luciferin (6mg/ mouse). B, Luciferase activity was quantified in the tumor area by BLI and 
expressed as photons/second/region of interest (ROI) (n=3 + stddev), arrowheads indicate 
polyplex applications. C, The luciferase activity in different organs was quantified. li, 
abbrevation for liver, lu for lung, ki for kidney, sp for spleen, tu for tumor . 
 
3.5. Evaluation of TNF gene expression in tumors and livers by qPCR 
To detect the transgene expression of pTNF plasmid in vivo, the transgenic 
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TNF expression induced by pTNF/G3-HD-OEI polyplexes in vivo at mRNA level 
was determined by qPCR and normalized to the expression of the GAPDH 
housekeeping gene. The relative total TNF mRNA level (both, endogeneous 
and transgenic TNF mRNA) in tumor and liver of mice from pTNF/G3-HD-OEI 
polyplexes treated group were significant higher than in pLuc/G3-HD-OEI 
polyplexes treated mice and untreated mice (fig. 5 A), and the TNF mRNA level 
in pLuc/G3-HD-OEI polyplexes treated mice was higher than in untreated mice 
(fig. 5 A). A higher level of TNF mRNA in tumor than in liver was found which 
indicates again that G3-HD-OEI polypelxes exhibits intrinsic tumor affinity, as 
shown in fig. 4. Utilizing properly designed primers, it was possible to 
distinguish between exogeneous and endogeneous TNF mRNA. By blasting 
the standard TNF with our codon optimal TNF sequences, the least similarity 
places were found out and designed the primers which were then evaluated by 
normal PCR to prove that they can only amplify transgenic TNF in 
pTNF/G3-HD-OEI polyplexes treated samples, whereas wild type TNF is not 
amplified. In the pTNF/G3-HD-OEI polyplexes treated group, the relative 
transgenic (or exogenous) TNF mRNA in tumor tissue is about 6 times higher 
than in the liver tissue (fig. 5 B). This might verify of success transgene 
expression of pTNF plasmid, as pTNF/G3-HD-OEI polyplexes application leads 
to efficient TNF transgene expression, at least, at the RNA level.    
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Fig. 5: Detection of pTNF/G3-HD-OEI polyplexes transgene expression in vivo by 
qPCR   
At 48 hours after pTNF/G3-HD-OEI polyplexes were intravenously injected into A/J mice 
bearing subcutaneous Neuro2A tumors, mice (n=3+ stddev) were sacrificed and tumor and 
liver tissue were collected. TNF expression in tumor tissue was determined at mRNA level 
by RT-qPCR and was normalized to the expression of the GAPDH housekeeping gene. All 
samples were done in duplicates. A, Relative TNF mRNA in tumor tissue and liver tissue; B, 
Relative transgenic TNF mRNA in tumor tissue of pTNF treated group was also determined 
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at mRNA level by RT-qPCR and was normalized to the expression of TNF mRNA in liver 
tissue. 
 
3.6. Evaluation the influence of pTNF/G3-HD-OEI polyplexes on 
endothelial cell density in tumors  
To evaluate the influence of TNF on endothelial cell in vivo, eight days after 
subcutaneous Neuro2A cell inoculation, mice were treated with 
pTNF/G3-HD-OEI or pLuc /G3-HD-OEI polyplexes every third day for three 
times totally, and at 17 days after Neuro2A tumor cell inoculation mice were 
sacrificed, tumor tissue resected and cryosection were prepared. The tumor 
cryosections were stained with a fluorescently labeled antibody directed 
against murine endothelial cell marker anti CD31 (also known as PECAM-1, 
Platelet Endothelial Cell Adhesion Molecule-1, a membrane protein 
constitutively expresses on the surface of endothelial cells). The staining 
results show the decreased CD31 expression in the tumor tissues from 
pTNF/G3-HD-OEI polyplexes treated mice (fig. 6) and hence a decreased 
vessel density in tumor microenviroument caused by the transgenic TNF after 
pTNF/G3-HD-OEI polyplexes application. 
 
Fig. 6 
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Fig. 6: Evaluation the influence of pTNF/G3-HD-OEI polyplexes on endothelial cell 
density in tumors   
Eight days after subcutaneous Neuro2A cell inoculation, mice were treated with 
pTNF/G3-HD-OEI or pLuc /G3-HD-OEI polyplexes every third day for three times totally. At 
17 days after setting, Neuro2A tumors were resected, tumor cryosections prepared and 
stained with a fluorescently labeled antibody directed against murine endothelial cell 
marker anti CD31 (orange), nuclei were counterstained with DAPI (blue). Slices were 
observed under Zeiss Axiovert 200 microscope with 10× objective magnification. 
 
3.7. Assessment of Caelyx® uptake and in tumor and tissue distribution 
and evaluation of Caelyx®-DiR accumulation by living image 
To assess how pTNF polyplexes treatment affect the accumulation of liposomal 
doxorubicine Caelyx® in tumor tissue, A/J mice bearing subcutaneous, 
syngeneic Neuro2A tumors were treated with pTNF polyplexes based on the 
biodegradable polymer G3-HD-OEI, and HuH7 hepatoma xenografts in SCID 
mice received pTNF polyplexes based on linear polyethylenimine carrying a 
peptide (GE11) selectively binding to the epidermal growth factor receptor, 
which is highly overexpressed in HuH7. After pretreating mice with pTNF 
polyplexes, Caelyx® was applied intravenously. Tumor and liver tissues were 
collected 24h thereafter and cryosections were prepared and observed under 
microscope. From the results of cryosection slices, we conclude that pTNF 
polyplexes application enhances accumulation of liposomal doxorubicine 
Caelyx in tumor tissue and led to nuclear localization of doxorubicine in tumor 
tissue in Neuroblastoma using G3-HD-OEI as gene carrier (fig. 7 A). The 
quantification results of Caelyx® concentration also showed that pTNF 
polyplexes pretreatment significantly enhanced the accumulation of Caelyx® in 
tumor tissue in Neuroblastoma using G3-HD-OEI as gene carrier, while the 
same trends were found in HuH7 hepatoma xenografts model using 
LPEI-PEG-GE11 (fig. 7 B) or G2-HD-OEI (fig. 7 B) as gene carrier. The 
enhancement was more significant when LPEI-PEG-GE11 was employed as 
gene carrier. This might due to the fact that LPEI-PEG-GE11 is based on linear 
polyethylenimine carrying a peptide (GE11) selectively binding to the epidermal 
growth factor receptor (EGFR), which is over-expression in HUH7 cells, thus 
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leading to pronounced endocytosis of polyplexes and subsequently high 
transgene expression efficiency. With the help of BLI, significantly enhanced 
tumor accumulation of Caelyx® fluorescently labeled with the lipid DiR emitting 
in the near infrared at 15 minutes (fig. 7 C) or 24 hours (fig. 7 C) after injection 
was observed. The fluorescence signals were quantified and results are 
showed in fig. 7 D. Further, when the organs were collected and imaged, 
significant enhancement of Caelyx®-DiR in tumor tissue and a certain decrease 
in liver tissue in pTNF/ LPEI-PEG-GE11 polyplexes treated mice were found 
(fig. 7 E). All these results suggest a TNF mediated increase of tumor blood 
vessel permeability augmenting the accumulation of liposomal 
chemotherapeutics.
 
Fig. 7 A 
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Fig. 7 D 
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Fig. 7 E 
Fig. 7: Assessment of Caelyx® uptake and in tumor and tissue distribution and 
evalution of Caelyx®-DiR accumulation by living image  
48h after a single intravenous injection of pTNF/G3-HD-OEI polyplexes into Neuro2A 
(Neuroblastoma) bearing mice (A), or pTNF/ GE11-PEG-PEI polyplexes into HUH7 
(human hepatocellular carcinoma) bearing mice (B), 5 mg/kg Caelyx® were injected 
intravenously. 24h later, tumors and liver tissues of mice were collected. A, Cryosections 
slices of tumors from Neuroblastoma model were fixed in methanol and observed under 
Zeiss Axiovert 200 microscope with 20 × objective magnification. B, Tumors from both 
models were homogenized in acidified isopropanol and doxorubicine quantified in a 
spectrofluorometer using a standard curve with defined Caelyx concentration. C, 
Immediately till 15 minutes or 24 hours after Caelyx®-DiR injection, mice were imaged in 
the IVIS imager with a CCD camera using the ICG filter set (Xenogen Ivis), and the signal 
of fluorescence in tumor tissue was measured. D, Average Radiance (p/s/cm
2
/sr) in tumors 
(15 minutes and 24 hours after injection) was quantified. E, 72h after Caelyx-DiR injection, 
mice were sacrificed and tumors and organs were collected and imaged in the IVIS imager 
with a CCD camera using the ICG filter set (Xenogen Ivis). 
 
3.8. Application of pTNF /G3-HD-OEI polyplexes in the subcutaneous 
murine neuroblastoma model Neuro2a 
Since many papers (Kircheis R 2002; Kursa 2003; Koppu 2010) indicated the 
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direct effect of TNF in inhibition of tumor growth, here, in order to see the 
therapeutic effect of pTNF/G3-HD-OEI polyplexes treatment in the murine 
neuroblastoma model, on the ninth day after Neuro2A cell inoculation, mice 
were treated with pTNF/G3-HD-OEI or pLuc/G3-HD-OEI polyplexes every third 
day, the tumor size and the body weight were measured continuously. From the 
results, we found that pTNF polyplexes treatment reduced tumor growth in 
murine neuroblastoma model when compared with Luciferase polyplexes 
treated group (fig. 8 A), however, obviously, pTNF polyplex treatment alone is 
not enough to inhibit the tumor growth for a long time. There is no significant 
change on body weight between these two groups (fig. 8 B), which indicates 
the undetectable side effect caused by pTNF polyplexes application. All 
experiments were repeated twice and exhibited the same tendency.            
  
 Fig. 8 A 
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Fig. 8: Application of pTNF polyplexes reduces tumor growth in the murine 
neuroblastoma model   
A, Eight days after Neuro 2A cells inoculation, mice were treated with pTNF/G3-HD-OEI or 
pLuc /G3-HD-OEI polyplexes every third day, and the tumor size was measured 
continuously, arrowheads showed the days poplyplexes applied; B, The body weight of 
mice were measured continuously. 
 
3.9. Application of pTNF/G3-HD-OEI polyplexes and Caelyx® in the 
subcutaneous murine neuroblastoma model  
Here, in order to evaluate the combined therapeutic effect of pTNF/G3-HD-OEI 
polyplexes and chemotherapy and the influence of pTNF polyplexes 
pretreatment on the therapeutic effect of chemotherapy in the murine 
neuroblastoma model, three rounds of systemic pTNF polyplexes application 
and subsequent Caelyx® treatment were performed in A/J mice carrying 
subcutaneous Neuro2A tumors . As the results shown, pTNF polyplexes 
application and subsequent Caelyx® treatment led to tumor growth inhibition 
lasting until eight days after the last treatment (fig. 9 A). The pictures of 
experimental mice showed vivid evidence that the tumor growth of mice treated 
with pTNF polyplexes and subsequent Caelyx® were significantly inhibited as 
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compared with mice pLuc polyplexes/Caelyx® treated, only Caelyx® treated or 
totally untreated (fig. 9 B). Almost all pTNF polyplexes/Caelyx® treated mice 
developed hemorrhagic tumor necroses. Necrosis was most pronounced in the 
center of the tumor, whereas hemorrhagic tumor necrosis was virtually not 
found in control animals and only rarely found in Caelyx® or pLuc 
polyplexes/Caelyx® treated animals (fig. 9 A, B, picture of representative mice 
shown). However, there was only in very few cases a complete eradication of 
the tumor in this model. This is consistent with other papers applying TNF as 
treatment in the murine neuroblastoma model (Kircheis R 2002). Moreover, in 
the retreated (or boost) model, an additional treatment cycle 6 days after last 
treatment was conducted with 7 out total 11 mice in the group, and the tumor 
size were monitored continuously. Re-growth of treated tumors could be 
inhibited by a second treatment cycle indicating that no resistance towards 
combined pTNF polyplexes /Caelyx® treatment occurred (fig. 9 C). 
Immunological staining of the tumor cryosection with a fluorescently labeled 
antibody directed against murine endothelial cell marker anti CD31 showed the 
significant decrease of CD31 expression in the tumors of re-treated mice as 
compared with non retreated mice (fig. 9 D), which indicates a decrease vessel 
density caused by pTNF polyplexes /Caelyx® retreatment, or to say, the 
transgenic TNF destroyed the endothelium. When CD31 fluorescence was 
quantified by image analysis using ImageJ software, less positive pixels per 
field in pictures from pTNF polyplexes /Caelyx® retreated mice were observed 
(fig. 9 E). All these results suggest that TNF pretreatment and subsequent 
Caelyx® chemotherapy do reduce the growth of tumor cells in vivo in murine 
neuroblastoma model, which could because that pTNF polyplexes 
pretreatment increase of tumor blood vessel permeability and augment the 
accumulation of liposomal chemotherapeutics.  
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Fig. 9 E 
Fig. 9: Application of pTNF/G3-HD-OEI polyplexes and Caelyx® in subcutaneous 
murine neuroblastoma model  
A, 10 days after subcutaneous inoculation of Neuro2A cells,mice were treated with 
intravenously applied pTNF/G3-HD-OEI or pLuc/G3-HD-OEI polyplexes every 4 days for 
three times respectively, and every  2 days after polyplex application Caelyx® was applied 
at a dose of 1.5mg/kg. The tumor size was measured continuously. B, The pictures of mice 
in different groups were taken at the day of last treatment. C, In the retreated (or boost) 
model, the same treatment as in A, only that 6 days after last treatment, an additional 
treatment cycle was conducted with 7 out total 11 mice in pTNF polyplexes /Caelyx® 
treated group, and the tumor size were monitored continuously. D, At 32 days after tumor 
cell inoculation, mice were sacrificed, and Neuro2A tumors were resected and tumor 
cryosections were stained with a fluorescently labeled antibody directed against murine 
endothelial cell marker anti CD31 (green), nuclei were counterstained with DAPI (blue). 
Slices were observed under Zeiss Axiovert 200 microscope (Carl Zeiss, Jena, Germany) 
with 10x objective magnification, and pictures were taken. E, CD31 fluorescence was 
quantified by image analysis, using ImageJ software. The parameter total number of 
positive pixels per field was analyzed for each image. 
 
3.10. Application of pTNF/G3-HD-OEI polyplexes and Caelyx® in the 
metastatic murine neuroblastoma model 
As we have found that pTNF polyplexes application synergizes with Caelyx® 
chemotherapy leading to the inhibition of tumor growth in subcutaneous murine 
neuroblastoma model, here we tried to find out the therapeutic effect of pTNF 
polyplexes/ Caelyx® treatment towards metastatic murine neuroblastoma 
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model. At 6 days after intravenous Neuro2A lenti Luc cells inoculation, mice 
were treated with pTNF /G3-HD-OEI or pdeTNF/G3-HD-OEI polyplexes every 
forth days for three cycles, and every second days after polyplexes application 
Caelyx® was applied at a dose of 1.5mg/kg. Bioluminescence imaging (BLI) 
was carried out after intraperitoneal injection of luciferin and luciferase activity 
was quantified in the tumor area (from back, flank and abdomen side) by BLI 
(fig. 10 A) and expressed as photons/second/region of interest (ROI) (n=10). 
Similar as in the subcutaneous murine neuroblastoma model, in the metastatic 
murine neuroblastoma model three rounds of systemic pTNF polyplexes 
application and subsequent Caelyx® treatment also led to tumor growth 
inhibition (fig. 10 A). Quantifying bioluminescence imaging (BLI) results as a 
measure for total tumor burden in fig. 10 B showed the significantly lower BLI 
signal of the tumor cells in pTNF polyplex/ Caelyx treated mice than in the 
pdeTNF polyplexes/ Caelyx® treated mice or untreated mice (pdeTNF, plasmid 
without promoter, used as the control plasmid of pTNF). At 6 days after the last 
treatment, mice were sacrificed, and tumor metastases in the body cavity were 
evaluated and pictures taken by camera. As the photos of mice show, there are 
clearly less and smaller visible tumor metastases within the organs in pTNF 
polyplexes/Caelyx treated mice, while there are obviously more tumor 
metastases were found in pdeTNF polyplexes/ Caelyx® treated mice or 
untreated ones (fig. 10 C). Almost all pTNF polyplexes/Caelyx® treated mice 
showed significantly inhibition of tumor growth and metastasis, while it was 
virtually not found in untreated animals and only rarely found in pdeTNF 
polyplex/ Caelyx® treated animals (fig.10 A, B, C, representative mice are 
shown). To find out more direct evidence for reduction of tumor, bowels 
(including heart, lung, liver, spleen, kidney, small and large intestine) were 
taken out and weighted, and the weight of tumors was calculated by deducting 
the average weight of visceral of mice (n=3+) without tumor cell inoculation but 
with the same treatment of polyplexes/Caelyx®. Compared with the control 
group, pTNF polyplex/ Caelyx treatment significantly decreased the tumor 
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weight in mice, while the tumor weight from pdeTNF polyplexes/ Caelyx® 
treated mice is also lower than the untreated group (fig. 10 D). This tendency 
among the three groups is consistent with the above described results for 
Bioluminescence imaging (BLI) and photos. Moreover, to observe the tissue 
lesions of mice, the collected organs were fixed in formalin and HE staining was 
performed. As it can be seen from the pictures of tissues slices, almost no 
tumors were found in kidney lung and spleen tissues. The pictures in fig. 10 E-1 
show the healthy, tumor free kidney, lung and spleen tissues. However, many 
metastatic tumors were found in the liver tissues. Hepatocytes and tumor cells 
can easily be distinguished by their color: Tumor cells are darker colored and 
slightly bluish. Morphological characteristics also show difference: while 
hepatocytes tend to have an angular shape, tumor cells seem to be round, no 
clear membrane boundary between cells, containing larger nuclei and therefore 
containing less stroma (fig. 10 E-2). There are obvious many metastatic tumors 
in livers from pdeTNF polyplexes/Caelyx® treated mice or untreated mice, 
while there are almost no tumor metastases in liver in the pTNF polyplex/ 
Caelyx® treated mice, and the livers appeared quite healthy and almost similar 
as the background group (mice without tumor cells inoculation) (fig. 10 E-2). In 
conclusion, all these results from Bioluminescence, figures of body cavities, 
tumor weight and the HE staining of tissue sections suggest that pTNF 
polyplexes pretreatment and Caelyx® chemotherapy does reduces the growth 
and metastasis of tumor cells in vivo in the metastatic murine neuroblastoma 
model, and that combining liposomal chemotherapeutic with TNF gene therapy 
leads to a synergistic effect on tumor reduction in both subcutaneous and 
metastatic murine neuroblastoma model.  
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Fig.  10 D 
Figures of HE Staining 
ⅠHealthy, tumor free spleen kidney and lung  
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ⅡMetastatic tumors in liver 
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Fig. 10: Application of pTNF/G3-HD-OEI polyplexes and Caelyx® in the metastatic 
murine neuroblastoma model 
At 6 days after intravenous inoculation Neuro2A lenti Luc cells, mice were treated with 
pTNF/G3-HD-OEI or pdeTNF/G3-HD-OEI polyplexes every 4 days for three times, and 
every 2days after polyplexes application, Caelyx® was applied at a dose of 1.5mg/kg. A set 
mice was left totally untreated as a control. A, Bioluminescence imaging (BLI) was carried 
out after intraperitoneal injection of luciferin and luciferase activity was quantified in the 
tumor area (from back, flank and abdomen side) by BLI and expressed as 
photons/second/region of interest (ROI) (n=10) ; B, Quantification results of the photon 
signal, expressed as photons/second/region of interest (ROI) ; C, At 6 days after last 
treatment, mice were sacrificed, and tumor metastases in the body cavity were observed 
and pictures taken by camera; D, Bowels (including heart, lung, liver, spleen, kidney, small 
and large intestine) were taken out and weighted, and the weight of tumors was calculated 
by deducting the average weight of visceral of mice (n=3+) without tumor cell inoculation 
but with the same treatment of polyplexes/Caelyx®. E, After the mice were sacrificed, 
organs were collected and fixed in formalin and the HE staining of organs were done, and 
slices were observed under Zeiss Axiovert 200 microscope. The obtained pictures were 
processed, using Adobe Photoshop CS5 for adjusting color and contrast adjustments and 
adding a scale bar. Fig. 10 E-1 shows the pictures of healthy, tumor free spleen kidney and 
lung, with 10×objective magnification, scale bar 0,5mm; fig. 10 E-2 shows the pictures of 
livers, with 10× or 20×objective magnification, scale bar 0,5mm, tumor cells in livers from 
pdeTNF or ctrl group are darker colored and slightly bluish, seem to be round and no clear 
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membrane boundary between cells, thus can been distinguished from hepatocytes easily.  
 
To find further evidence of the transgene expression of pTNF polyplexes in vivo 
in metastatic murine neuroblastoma model, especially at protein level, we 
employed an immunostaining method. At 6 days after last treatment, mice were 
sacrificed and dissected; the tumor tissues collected and cryosection were 
prepared. Microslices of tumors were immunostained with rabbit anti murine 
TNF as first antibody and Alexa Fluor 488 labeled goat-anti- rabbit secondary 
antibody and the stained sections observed under a microscope. Pictures from 
both pdeTNF and pTNF polyplexes treated groups showed fluorescence which 
might be due to the fact that TNF could be produced by either the host or 
malignant cells originating from inflammatory processes, an effect naturally 
occuring in the body (Balkwill 2009). Considering natural occurrence of TNF 
seems fairly considerable. Nevertheless, there was a notable difference: not 
only the intensity of the fluorescence was much stronger in the pTNF 
polyplexes treated group, but also the source of the signal was located closer to 
the cells than in control group, which might verify successful transgene 
expression of pTNF plasmid. Hence, pTNF/G3-HD-OEI polyplex application 
indeed led to efficient TNF transgene expression in Neuro2A metastases. As 
shown in the power panels of fig. 10. F, possibile dysfunctional staining was 
excluded by the use of a control group, which did not show fluorescence - 
indicating the fluorescent second antibody (Alexa Fluor 488 labeled goat-anti- 
rabbit) has only specific binding ability to the first antibody (rabbit anti-mouse 
TNF ).  
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Fig. 10 F: Detection of pTNF polyplexes transgene expression in vivo by 
immunostaining 
Mice were treated as mention in fig.10. Then, at 6 days after last treatment, mice (n=3) 
were sacrificed and dissected, tumor tissues were collected and cryosectioned. The 
microslice of tumor were immnostained with anti-TNF first antibody and Alexa Fluor 488 
labeled goat-anti- rabbit second antibody and the stained slice were observed under Zeiss 
Axiovert 200 microscope with 20× objective magnification. The figures in the down line 
showed the control for unspecific second antibody attachment. Green: TNF, blue: cell 
nuclei (DAPI).  
 
3.11. Application of pTNF /LPEI-PEG-GE11 polyplexes and Caelyx® in the 
metastatic colon adenocarcinoma model 
As we have found in subcutaneous and metastatic murine neuroblastoma 
models that pTNF polyplexes application synergizes with the Caelyx® 
chemotherapy, we also investigated how pTNF and Caelyx® treatment will 
affect cancer models other than murine neuroblastoma, such as metastatic 
human colon adenocarcoma. Here we tried to find out a possible therapeutic 
effect of pTNF polyplexes and Caelyx® on intrasplenically injected LS174T 
colon adenocarcinoma liver metastases in nude mice. At 3 days after the LS 
174T lenti Luc cells were intrasplenically inoculated, mice were treated with 
pTNF/LPEI-PEG-GE11 or pdeTNF/ LPEI-PEG-GE11 polyplexes every third 
days for three cycles, and every second days after polyplexes application, 
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Caelyx was applied at a dose of 1.5mg/kg. Bioluminescence imaging (BLI) was 
carried out after intraperitoneal injection of luciferin and luciferase activity 
quantified in the tumor area (from abdominal side) by BLI (fig.11 A) and 
expressed as photons/second/region of interest (ROI) (n=10). Similar as in the 
subcutaneous and metastatic murine neuroblastoma model, three rounds of 
systemic pTNF polyplex application and subsequent Caelyx® treatment also 
led to tumor growth inhibition of LS174T lenti Luc tumors: bioluminescence 
imaging (BLI) results in fig. 11 A and the quantification results of BLI in fig. 11 B 
led to significantly lower BLI signal of the tumor cells when compared to then 
control groups. There was also certain therapeutic effect of Caelyx and control 
polyplexes, as reduced tumor growth was also observed in pdeTNF and 
Caelyx® treated mice when compared with untreated mice. At 1 day after the 
last treatment, mice were sacrificed and dissected to monitor the tumor 
metastases in the visceral of mice (particularly the supposed metastasis organ 
liver and the tumor inoculation site spleen). As the photos of livers demonstrate, 
there are significantly less tumor metastasis on the surface of livers from pTNF 
polyplexes/ Caelyx® treated mice, while obviously more tumor metastasis were 
observed on the surface of livers from mice either pdeTNF polyplexes/ Caelyx® 
treated or untreated (fig. 11 C). There is one liver from an untreated mouse, 
where almost the whole liver is covered with tumors with almost no healthy liver 
tissue left.The growth of tumor cells in the spleens from pdeTNF polyplex/ 
Caelyx® treated or untreated mice was so fast that half of the spleen surface is 
covered with tumor tissue and the spleens are swollen or seriously expanded. 
In contrast, there are far less tumors on the surface of spleens of pTNF 
polyplexes/ Caelyx® treated mice. To give a quantitative measure for tumor 
burden, we collected and weighted liver and spleen. Compared with the control 
group, pTNF polyplex/ Caelyx® treatment led to significantly decreased spleen 
and liver weight. Also the weight of organs from pdeTNF polyplex/Caelyx® 
treated mice is lower when compared to totally untreated and tumor bearing 
mice (fig. 11 D), which indicates the therapeutic effect of Caelyx® in this cancer 
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model. Then, the concentration of total protein and the bioluminescence signal 
in supernatant of liver lysates were measured and expressed as relative light 
units (RLU) per μg total protein. Significantly lower Bioluminescence signal 
strength in the liver lysate which means significantly less tumor cells in the 
livers are found in pTNF poplyplexes/ Caelyx® treated mice than pdeTNF 
polyplexes/ Caelyx® treated or untreated mice (fig. 11E). However, no lower 
Bioluminescence signal strength was found in livers from pdeTNF polyplexes/ 
Caelyx® treated mice than untreated mice (fig. 11 E). Moreover, to observe the 
tissue lesions of mice, the supposed sites of metastasis, liver, and the tumor 
cell inoculated organ spleen were collected, fixed in formalin and the HE 
staining of organs performed. Hepatocytes and tumor cells in liver sections can 
be easily distinguished by their color, as tumor cells appear darker colored and 
slightly bluish. Morphological characteristics also show differences: while 
hepatocytes tend to have an angular shape, the tumor cells seem to be round, 
no clear cell membrane boundary between cells is visible, and some of them 
even containing multiple nuclei and therefore also less stroma (fig. 11 F-1). As 
seen in the pictures of stained liver slices, there are obviously multiple sites of 
tumors metastases in the liver from pdeTNF polyplex / Caelyx® treated or 
untreated mice, and in almost all mice had more than half of the liver is invaded 
with tumors. Many tumors do not show signs of necrosis as it can be seen from 
the merged big tumors on the left side of fig. 11 F-1, and only some of the very 
big tumors developed necrosis in the middle of the tumor lesion. The tumors 
metastases in liver from the pTNF polyplexes / Caelyx® treated mice are 
significantly reduced, as much less tumors were found: only one obvious tumor 
was found within four different livers, which already developed a central 
necrosis albeit relatively small in size (fig. 11 F-1). These results of HE staining 
also demonstrate that pTNF polyplexes / Caelyx® treatment slowed the growth 
of cancer cells or prevented the metastasis of the tumor cells in liver. As seen 
on the pictures of stained spleens, it was obvious that all spleens from three 
groups carry tumors; almost the whole spleens where invaded with tumor cells 
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and no tumor free spleens were observed in mice either pdeTNF polyplexes/ 
Caelyx® treated or untreated. Fewer tumors were found in mice pTNF 
polyplexes/ Caelyx® treated, and a higher fraction of tumors developed 
necrosis (fig. 11 F-2). However, even the spleens where no tumors were visible 
on the surface, were also seriously tumor infected (fig. 11 F-2). In conclusion, 
all these results from bioluminescence, macroscopic observations and weight 
of the tumor infected organs liver and spleen, and the HE staining of tissue 
section suggest that a combination of pTNF polyplexes pretreatment and then 
Caelyx® chemotherapy does reduce the growth and metastasis of tumor cells 
in vivo in the intrasplenic liver metastatic colon adenocarcinoma model, and 
that combining liposomal chemotherapeutic with TNF gene therapy leads to a 
synergistic effect on tumor reduction in this cancer model. 
 
 
Fig. 11 A 
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Fig. 11 E 
 
Figures of HE staining  
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Left: merged big tumors from several single pictures; Right: single pictures; Pictures were 
observed with 10× objective magnification, scale bar 0,5mm  
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Left: merged big tumors from several single pictures; Right: single pictures; Pictures were 
observed with 10× objective magnification, scale bar 0,5mm  
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Left: merged big tumors from several single pictures; Right: single pictures; Pictures were 
observed with 10× objective magnification, scale bar 0,5mm  
Fig. 11 F-1 
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Ⅱ Tumors in spleen 
ctrl 
 
pdeTNF+Caelyx® 
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Fig. 11 F-2 
Fig. 11: Application of pTNF/LPEI-PEG-GE11 polyplexes and Caelyx® in the 
metastatic colon adenocarcinoma model 
At 3 days after LS 174T lenti Luc cells where intrasplenic inoculated, mice were 
intravenously injected with pTNF / LPEI-PEG-GE11 or pdeTNF/ LPEI-PEG-GE11 
polyplexes every 3 days for three times, and every 2 days after polyplexes application, 
Caelyx® was applied at a dose of 1.5mg/kg. As a further control, tumor inoculated mice 
were left untreated. A, Bioluminescence imaging (BLI) was carried out after intraperitoneal 
injection of luciferin and luciferase activity was quantified in the tumor area (from back, 
flank and abdominal side) by BLI and expressed as photons/second/region of interest (ROI) 
(n=10); B, Quantification results from fig. 11 A expressed as photons/second/region of 
interest (ROI) ; C, At 1 day after last teatment, mice were sacrificed and dissected to 
observe the metastasis of tumor cells in the visceral of mice (particularly liver and spleen), 
and the pictures of livers and spleens were taken (n = 11) ; D, Collected livers and spleens 
were weighted and differences statistically analyzed (n=11, T-Test, * p<0.05, ** p<0.01, *** 
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p<0.001) E, Frozen livers were grinded to powders with liquid nitrogen which were then 
lysed with protein lysis buffer, the concentration of total protein and bioluminescence signal 
in supernatant of liver lysates were measured and expressed as relative light units (RLU) 
per μg total protein. F, After the mice were sacrificed and dissected, livers and spleens 
were collected and fixed in formalin. HE staining was done, and slices were observed 
under Zeiss Axiovert 200 microscope. The obtained pictures were processed, using Adobe 
Photoshop CS5 for adjusting color and contrast adjustments and adding a scale bar and 
merging single pictures into bigger ones (as seen at the left of the pictures of livers). Fig. 11 
F-1 shows the pictures of livers, with 10×objective magnification, scale bar 0,5mm; Left: 
merged big tumors from several single pictures. Tumor cells in livers from in pictures are 
darker colored and slightly bluish, seem to be round and no clear membrane boundary 
between cells, thus can been distinguished from hepatocytes easily. Fig. 11 F-2 shows the 
pictures of spleens, with 10×objective magnification, scale bar 0,5mm. 
Discussion                                                                                                                                                 84 
4. Discussion 
4.1. Novel plasmid pTNF with human CMV enhancer and CpG free 
backbone induces persistent transgene expression in vitro  
It was shown that CpG-dinucleotides in the plasmid DNA have a strong 
negative effect on the duration of transgene expression (Yew 2000; Yew 2002; 
Hodges 2004; Hyde 2008; Mitsui 2009). In the plasmid, the hCMV enhancer is 
more efficient driving transcription in human cells than the murine analogue 
(Isomura 2003). Our results suggest that the novel plasmid vector with CpG 
free backbone and an optimized promoter-enhancer combination (with hCMV 
as enhancer and EF1 as promoter) is definitely powerful at inducing sustained 
and high transgene expression and could be used in vitro (fig. 1 A, B,C) and in 
vivo for sustained gene therapy. These results are consistent with several 
papers showing that with a CpG-free pDNA expression vector sustained in vivo 
transgene expression can be achieved (Navarro 2010), without inflammatory 
reactions in the lung (Hyde 2008). 
 
4.2. Secreted TNF increases endothelial cell permeability in a transwell 
system, but exerts only moderate toxicity towards tumor cells. 
Our results of the transwell assay (fig. 2 B) show that secreted transgenic TNF 
induced by pTNF polyplex transfection increased endothelial cell permeability, 
which might due to TNF mediated apoptosis of some endothelial cells and then 
an enhancement of leakage. This is consistent with other papers (Nawroth 
1986; Palladino 1987; Nawroth 1988; Clauss 1990; Gasparri 1999; Lienard 
1999). Meanwhile, we found TNF did not exert direct tumor cell toxicity on 
HUH7, Neuro2A, U87MG and MBA-MD-231 cell lines, while exerting a 
moderate toxicity on MBA-MD-453 and BT549 cell lines (fig. 2 C). The different 
sensitivity of the cell lines to TNF could be due to the abundance of the TNF 
receptor. All these cell lines are known to express low levels of TNF-R1. Tumor 
cell lines including gliomas (Duan 2001; Carroll-Anzinger 2006) and hepatoma 
(Plümpe 2000) are resistant against apoptosis initiated by treatment with TNF-α, 
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but can be sensitized through costimulation with metabolic inhibitors (inhibitors 
of protein or RNA synthesis), such as actinomycin D, CDDP, cyclohexamide or 
mitomycin C. Even TNF sensitive cell lines such as L929 always respond more 
sensitive to the TNF treatment when applied together with inhibitors of protein 
or RNA synthesis. As concluded by some papers, TNFR 2 (TNF-R75), must be 
responsible for the strongly enhanced systemic toxicity of murine TNF (Ostade 
1993), while some other papers suggested that although only sensitive cell 
lines express transcripts for p75 TNF receptor 2, changes in TNF receptors 
were not found to contribute to the susceptibility for TNF (Duan 2001). Many 
papers suggested that the toxicity of TNF towards malignant cells might 
dependent on the activation of TNFR-1 and Fas-mediating the apoptosis 
pathway. TNF-R1-mediated cytotoxicity can be selectively inhibited under 
conditions in which Fas-mediated cell death is not affected. Activation of both 
receptors results in synergistic signaling of apoptosis (Wong 1994). It was 
reported that in tissue culture studies, purified or recombinant TNF was 
selectively toxic for malignant cells, as were TNF-containing supernatants from 
activated macrophages (Colotta 1984). However, many of these data were 
generated in the presence of metabolic inhibitors such as actinomycin D, 
cyclohexamide or mitomycin C (Colotta 1984; Sugarman 1985; Dealtry 1987) 
or in combination with interferon-γ (IFN γ) (Williamson 1983; Fransen 1986). It 
might be that the antitumor activity of TNF depends on indirect mechanisms 
associated with selective destruction of the tumor-associated vascular bed and 
TNF-induced alteration of endothelial barrier function and of immune 
mechanisms rather than having toxic effects directly on tumor cells. 
 
4.3. The plasmid pRGD-TNF leads to targeting TNF expression and 
pTNF-mir143 leads to selective TNF expression 
Similar as Natasa Zarovni and some other scientists did (Zarovni 2004), here, 
we employed the sequence of RGD motif  (which can been recognized, bound 
and internalized by αvβ3 integrins, belonging to a family of cell-surface proteins, 
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with high expression on  endothelium) in our pTNF plasmid to target TNF 
transgene expression to endothelium. Integrins are dimeric adhesion receptors 
that mediate cellular attachment to the extracellular matrix (ECM) or to adjacent 
cells. Integrin-mediated cell–matrix interactions regulate often divergent 
biological events including cell adhesion, migration, proliferation, differentiation 
and survival (Giancotti 1997). The αvβ3 integrin plays a fundamental role 
during the angiogenesis process by inhibiting endothelial cell apoptosis 
(Scatena 1998). 3-type integrins (αvβ3 and αIIbβ3) are expressed in multiple 
cell types including invasive tumor cells, osteoclasts, activated endothelial and 
smooth muscle cells, platelets, megakaryocytes and macrophages (Sloan 
2006). Endothelial enhanced the expression of αvβ3 integrin in the tumor 
vasculature (Sloan 2006). Besides, after TNF treatment ,endothelial cells may 
increase the activation and ligation of αvβ3 while decreasing the activation and 
ligation of α5β1-integrins to facilitate cell migration (GAO 2002). Compared with 
pTNF plasmid, the plasmid containing vasculature-targeting peptide RGD gene 
fusing with mature TNF gene, pRGD-TNF, induced higher TNF biological 
activity into the medium which led to higher cytotoxicity on L929 indicator cells 
than pTNF (fig. 3 A).This could because that RGD motif attached on L929 
mouse fibroblasts through αvβ3 integrin (expressed by L929 cells)-mediated 
interactions (Katagiri 1996; Karakecili 2007) and then leads to higher 
endocytosis of TNF and subsequently TNF-mediated cytotoxicity. When we 
applied the pRGD-TNF/G3-HD-OEI polyplexes in vivo in the subcutaneous 
murine neuroblastoma model, we found that three rounds of intravenous 
pRGD-TNF polyplex application led to inhibition of tumor growth in mice (fig. 3 
B); however, the inhibition effect was only moderatly enhanced compared to 
pTNF polyplexes treatment and the effect is not as significant as some papers 
(Zarovni 2004) declared. This might either suggests that RGD-TNF expressed 
directly in tumor cells is not reaching the endothelias cells in sufficient amounts 
or that the targeting TNF expression might also not enough for the tumor 
inhibition without chemotherapy treatment; even it is most expressed in 
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vasculature around the tumor (or tumor microenvironment). This will be 
investigated in future research projects. 
 
As mention in section 1.3.3., in view of the natural function of microRNA and the 
specific abundance of miR-143 in different tissues, here we construct 
pTNF-mir143 by inserting miR-143 targeting sequence into plasmid pTNF. We 
found the plasmid containing miR-143 targeting sequence (pTNF-miR143) do 
lead to lower TNF expression in PSMC (primary porcine smooth muscle cells, 
high level of miR-143, Florian Kopp, unpublished results) while no influence 
towards PC3 tumor cell line (low in miR-143, Florian Kopp, unpublished results) 
(fig. 3 C), which might indicate that when applied in vivo, pTNF-miR143 
plasmid might selectively TNF transgenic expression in tumor cells, while 
reducing the transgene expression in in other tissues besides tumor tissue and 
lead to lower related side effect. However, the miR-143 targeting sequence 
containing plasmid also decreased the expression of TNF in murine 
neuroblastoma (Neuro2A) cell line (fig. 3 D), which suggests that not all tumor 
cell line have a low level of miR-143 , and the application of miR-143 targeting 
sequence in selectively transgene expression also dependent on tumor types. 
 
4.4. pTNF/G3-HD-OEI poplyplexes induces transgenic TNF gene 
expression in vivo 
Here, the transgenic TNF expression induced by pTNF polyplexes in vivo was 
determined by qPCR at mRNA level. The relative total TNF mRNA level in both 
tumor and liver of mice from pTNF polyplex treated mice is significantly higher 
than in pLuc polyplex treated and untreated mice (fig. 5 A), which verifies that 
pTNF polyplex application leads to efficient expression of transgenic TNF in 
vivo, at least at mRNA level. Moreover, the transgenic TNF could also stimulate 
the endogenous TNF expression. TNF binding to TNFR1 induces a range of 
inflammatory mediators and growth factors through activation of the AP1 
transcription factors or IκB kinases (IKKs) that, in turn, activate nuclear 
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factor-κB (NF-κB), which then leads to inflammation and more TNF expression 
(Balkwill 2009). Meanwhile, the TNF mRNA level in pLuc polyplexes treated 
mice is also higher than in completely untreated mice.This could be due to 
inflammation caused by polyplex treatment inducing the initiation of the 
intracellular signal pathway leading to expression of inflammatory factors such 
as TNF and IL-6. To have direct evidence of the protein expression of TNF 
induced by pTNF polyplex application in vivo in the metastatic murine 
neuroblastoma model, we employed an immunostaining method. Pictures from 
both pdeTNF and pTNF treated groups show fluorescent staining specific for 
TNF. It is likely that the diffuse fluorescence found in all anti-TNF stained 
specimens originates from inflammatory processes intrinsically occuring in the 
body (either produced by the host or by malignant cells (Balkwill 2009)), while 
the distinct, strong fluorescence shown in fig. 10 F indicates higher TNF- α 
levels in vicinity to the tumor cells. Considering the affected cells were 
producing TNF- α at higher dose, this leads to the verification of positive 
treatment with the plasmid. 
 
4.5. Application of pTNF polyplexes decreases endothelial cell density in 
tumor 
Several evidences suggest that the antitumor activity of TNF depends on 
indirect mechanisms associated with selective destruction of the 
tumor-associated vascular bed. Our results of trans-well experiments show, 
that secreted TNF increases endothelial cell permeability, which might be due 
to the decreased endothelial cell density caused by pTNF/G3-HD-OEI 
polyplexes treatment. This is consistent with staining results in vivo showing the 
decreased CD31 expression in the tumor tissues from pTNF/G3-HD-OEI 
polyplexes treated mice (fig. 6) proving the decreased vessel density in tumor 
microenviroument caused by the transgenic TNF after pTNF/G3-HD-OEI 
polyplex application. 
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4.6. Application of pTNF polyplexes enhances accumulation of liposomal 
doxorubicine Caelyx® in tumor tissue and leads to nuclear localization of 
doxorubicine, while no significant effect was found on PEG-QD 
As mention in section 1.2.4., it is reported in several publications that low doses 
of TNF Increase tumor blood vessel permeability, thus augmenting tissue 
concentrations of hemotherapeutic drugs (Nawroth 1986; Palladino 1987; 
Nawroth 1988; Clauss 1990; Gasparri 1999; Lienard 1999), as the observed 
synergy between TNF and chemotherapy in locoregional treatment of patients 
with advanced tumors of the limb (Lienard 1999). We found that pTNF polyplex 
application enhances accumulation of liposomal doxorubicine Caelyx® in tumor 
tissue, in both Neuro2A murine neuroblastoma model using G3-HD-OEI as 
gene carrier and in HUH7 hepatoma xenografts model using GE11-PEG-PEI or 
G2-HD-OEI as gene carrier (fig. 7 B), and it led to nuclear localization of 
doxorubicine (fig. 7 A). Moreover, significantly enhanced tumor accumulation 
of Caelyx® fluorescently labeled with the lipid DiR emitting in the near infrared 
at 15 minutes or 24 hours after injection was observed by in vivo imaging (fig. 7 
C), and the quantification results of the signal of fluorescence (fig. 7 D) 
exhibited the same tendency. While more convincing results were observed in 
the results of organs image (fig. 7 E), as there was the significant enhancement 
of Caelyx®-DiR in tumor tissue and a slight decrease in liver tissue in the TNF 
polyplex pretreated group. All these results suggest a TNF mediated increase 
of tumor blood vessel permeability augmenting the accumulation of liposomal 
chemotherapeutics. However, when we used PEG-QD (coating Quantum dots 
with PEG, with the size of about 80nm, zeta-potential of -0.42) fluorescence 
signal in living image instead of Caelyx®-DiR, there is no significant 
enhancement of the accumulation of Caelyx® in tumor tissue was found. This 
could be explained by a possibly too short circulation time of PEG-QD (with only 
a few hours half life in vivo, even when Quantum dots coated with PEG 
(Andreas Offenhäusser 2009)) in comparison to Caelyx®, which reportedly 
circulates for >24h in the blood stream (Seynhaeve 2007). It was reported, 
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twelve hours after injection, 51 ±25% of the liposomal doxorubicine was still 
present in the blood circulation, while even after 72 h, still 15 ± 2% of the 
liposomes were measured in the circulation (Seynhaeve 2007). 
 
4.7. Application of pTNF polyplexes reduces tumor growth in the 
subcutaneous murine Neuroblastoma model 
Neuroblastoma is the most common extra cranial solid cancer in childhood and 
the most common cancer in infancy. It is one of the few human malignancies 
known to demonstrate spontaneous regression from an undifferentiated state to 
a completely benign cellular appearance. Their unpredictability and high rate of 
metastasis combined with their malignant character make them though a 
challenge for therapy. Consequently, different efforts were taken in treating this 
tumor type. Meanwhile, some of those features, such as the easy 
establishment of the mice model in A/J and so on all favor the use of 
neuroblastoma for research use. Since many papers declared the direct effect 
of TNF in inhibition of tumor growth, we evaluated the therapeutic effect of 
pTNF/G3-HD-OEI polyplexes treatment in the Neuro2a murine neuroblastoma 
model and showed that application of pTNF/G3-HD-OEI polyplexes reduces 
tumor growth in mice. 
The mechanisms how TNF functions in tumor therapy might be complicated. As 
mentioned in section 1.2.4., both isoforms of TNF (membrane bound and 
soluble TNF) bind two distinct receptors that are ubiquitous, TNF-R1, and 
TNF-R2 (Dembic Z 1990). It is an apoptotic pathway initiated by the clustering 
of death domain containing proteins upon the combination of TNF with the 
related receptor (Tartaglia LA 1993; Grell M 1994). Many papers (Kircheis R 
2002; Kursa 2003; Koppu 2010) declared the direct effect of TNF in inhibition of 
tumor growth, our results of murine neuroblastoma model (fig. 8 A) also 
showed that pTNF polyplexes reduces tumor growth in the murine 
neuroblastoma model when compared with luciferase polyplexes treated group, 
while there is no significant change in body weight (fig. 8 B) between these two 
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groups,  suggesting no significant side effect caused by pTNF polyplex 
treatment. However, as late as 17 days aftertumor setting, the tumor already 
grew quite big and mice had to be sacrificed, which also suggest that TNF alone 
is not enough in significantly delaying tumor growth. The therapeutic effect is 
not as good as compared with results declared by Swati Koppu et al. (a rapid 
and sustained tumor regression over one month, with longterm survival of 
100% of the animals (90% complete response, 10% partial response))(Koppu S. 
2010), this might due to the dose dependency principal, Swati Koppu et al. 
treated mice daily (50µg DNA) for ten days , while we only treated mice three 
times for every three days. However, the results could be also consistent with 
publications, which declare that TNF is only in combination with metabolic 
inhibitors that its cytotoxic potential is unmasked, and the antitumor activity of 
TNF depends mainly on indirect mechanisms associated with selective 
destruction of the tumor-associated vascular bed and TNF-induced alteration of 
endothelial barrier function, and of immune mechanisms rather than having 
toxic effects directly on tumor cells (Balkwill 2009). 
 
4.8. The combined therapeutic treatment of pTNF polyplexes and 
Caelyx® inhibits tumor growth in the subcutaneous murine 
neuroblastoma model 
Our results found that in Neuro2A murine neuroblastoma model, three rounds 
of systemic pTNF polyplexes application and subsequent Caelyx® treatment 
led to tumor growth inhibition lasting until eight days after the last treatment (fig. 
9 A). The pictures of mice after last treatment (fig. 9 B) also showed that the 
tumor growth of mice treated with pTNF polyplexes and Caelyx® were 
significantly growth inhibited when compared with mice treated with pLuc 
polyplexes and Caelyx® or completely untreated. Besides, re-growth of treated 
tumors could be inhibited by a second treatment cycle indicating that no 
resistance towards combined pTNF polyplexes/ Caelyx treatment occurred (fig. 
9 C). Immunological staining of the tumor cryosection with a fluorescently 
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labeled antibody directed against the murine endothelial cell marker CD31 
showed the significant decrease of CD31 expression in the tumors of  
re-treated mice when compared with non retreated mice (fig. 9 D), which 
indicates a decrease in vessel density caused by the transgenic TNF. All these 
results suggest that a TNF pretreatment and then Caelyx® chemotherapy does 
reduce the growth of tumor cells in vivo in mice, which could because that TNF 
pretreatment increases of tumor blood vessel permeability and augments the 
accumulation of liposomal chemotherapeutics. These results are consistent 
with many papers which declare that TNF alone was ineffective in their setting 
but synergized with melphalan chemotherapy in a rat osteosarcoma ILP model, 
with mild hyperthermia optimizing the anti-tumor effect (de Wilt 1999). A 
combination of TNF and doxorubicin had comparable effects in rat sarcoma 
models (van der Veen 2000). Previous results observed in our lab that 
enhanced therapeutic effects was reached in a murine B16F10 melanoma 
model by the combination of tumor-targeted TNF gene therapy with liposomal 
doxorubicin DOXIL® (Wagner E. 2004). It appears that low doses of TNF 
increase tumor blood vessel permeability (Seynhaeve 2007), thus augmenting 
tissue concentrations of chemotherapy and destroying the tumor vasculature. 
 
4.9. The combined therapeutic treatment of pTNF polyplexes and 
Caelyx® inhibits the tumor growth in the metastatic murine 
neuroblastoma model 
While some tumors are benign which do not invade or metastasize and can be 
removed from the body without further spreading, other tumors cells display 
uncontrolled growth, invasion that intrudes upon and destroys adjacent tissues, 
metastasis, or spreading to other locations in the body via lymph or blood, 
called malignant tumors. While the benign tumors usually can be removed by 
surgery, the malignant and metastatic tumors are often uncurable, metastasis 
causes most cancer deaths, yet this process remains the most poorly 
understood component of cancer pathogenesis. Chaffer et al suggested that 
Discussion                                                                                                                                                 93 
metastasis can be portrayed as a two-phase process: the first phase involves 
the physical translocation of a cancer cell to a distant organ, whereas the 
second encompasses the ability of the cancer cell to develop into a metastatic 
lesion at that distant site , which named colonization (Christine L.Chaffer 2011). 
Neuroblastoma is one of the few human malignancies, their unpredictability and 
high rate of metastasis combined with their malignant character make them 
though challenge for therapy.  
Here we evaluated the effect of combined treatment of pTNF polyplexes and 
Caelyx® in the Neuro2A metastatic murine neuroblastoma, and found similar 
effect on inhibition of the tumor growth as in the subcutaneous murine 
neuroblastoma model. The similar therapeutic effect found in metastatic model 
might be due to the idea shared by Sugino et al.(Sugino 2002): the metastasis 
doesn‘t origin from a ―cancer stem cell‖, but an aggregation of tumor cells, 
surrounded by epithelia, therefore preserving its organisation. It is possible that 
some cell aggregates were formed after inoculation and showed embolus 
behavior – with or without the ability to pass the vessel walls. The low doses of 
TNF increase tumor blood vessel permeability (Seynhaeve 2007), thus 
augment tissue concentrations of chemotherapy in the metastatic tumors which 
are located in the vincity of a main blood vessel and then enrich in microvessels, 
subsequently lead to the enhanced therapeutic effect caused by chemotherapy. 
As Bioluminescence imaging (BLI) results (fig. 10 A) and its quantification 
results (fig. 10 B) show, signals of luminescense of the tumor cells are 
significantly lower in mice pTNF polyplexes/ Caelyx® treated than mice 
pdeTNF polyplexes / Caelyx® treated or untreated mice. The photos of mice 
body cavity at 6 days after tumor cell inoculation (fig. 10 C) showed that mice 
treated with pTNF polyplexes/ Caelyx® do have significantly less metastatic 
tumors and the total tumor burden in mice was significantly decreased (fig. 10 
D) when compaed to the pdeTNF/Caelyx® treated or untreated mice. As 
figures of HE staining showed, in all groups almost no tumors were found in 
kidney, lung or spleen (fig. 10 E-1). However, many metastatic tumors were 
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found in the liver (fig. 10 E-2). This is consistent with the first published 
description of this metastatic Neuro2A model in A/J mice (Amirkhosravi A. 
1997). The high metastatic tumor cells in liver in this tumor model was 
surprising,  since  in a tail vein model of metastasis, the organ of first encounter 
is the lung and more than 90% of injected cells are initially trapped in the lungs 
(Amirkhosravi A. 1997). The exact reason might be complicated, and one 
possible explanation suggested by Amirkhosravi et al. is like this: it is likely that 
spread occurred beyond the lung stems from cells released from lung 
metastases into the arterial circulation. The liver provides more favorable 
conditions for the growth of this neuroblastoma cell line than the lung, which 
may be also due to availability of appropriate growth factors in the liver or an 
appropriate match of cell receptors and binding ligands. Moreover, other 
researchers also provided many other reasons. The formation of metastases in 
certain favored target organs may be influenced by structural differences in the 
capillaries of various tissues. In certain tumor types, the layout of the circulation 
may be the major determinant of metastatic tropism. Organ-specific homing 
may also constitute an active process, where tissue and cancer cell–specific 
features determine metastatic dissemination. The expression by metastasizing 
cancer cells of specific proteins (for example, integrins) seems to play a key 
role in this process (Christine L.Chaffer 2011). Thus, the preference of liver 
metastases in metaststic murine neuroblastoma model could also due to both 
the layout of the circulation and the organ-specific homing. We found many 
tumor metastases in livers of pdeTNF polyplexes/ Caelyx® treated or untreated 
mice, while there were almost none found in livers of the pTNF 
polyplexes/Caelyx® treated mice, which are almost as similar healthy as the 
background group (mice without tumor cells inoculation) (fig. 10 E-2). Here, all 
these results we got from Bioluminescence, figures of mice body cavity, tumor 
weight and the HE staining of tissue section suggest that a TNF pretreatment 
and then Caelyx® chemotherapy do reduce the growth and metastasis of tumor 
cells in vivo in the metastatic murine neuroblastoma model, and that combining 
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liposomal chemotherapeutic with TNF gene therapy leads to a synergistic effect 
on tumor reduction in this cancer model, All these results in the Neuro2A 
murine neuroblastoma model come to the conclusion that low doses of TNF 
increase tumor blood vessel permeability (Seynhaeve 2007), thus augmenting 
tissue concentrations of chemotherapy and destroying the tumor vasculature in 
both subcutaneous and metastatic murine neuroblastoma model. 
 
4.10. The combined therapeutic treatment of pTNF polyplexes and 
Caelyx® inhibits the tumor growth in metastatic colon adenocacinoma 
model 
Almost all colon cancers are primary adenocarcinoma, which has its origin in 
the cells of glandular structures in the inner layer of the colon. The malignancy 
then spreads first into the wall of the colon and potentially into the lymphatic 
system and other organs. Colon cancer is the third most common cancer in 
both men and women in North America and Western Europe. Colon 
adenocarcinoma can be treated, with 50 percent of patients surviving for at 
least five years, however, colon cancer survival is directly related to detection 
and the type of colon cancer involved. Surgery remains the primary treatment, 
while chemotherapy and/or radiotherapy are used to reduce the likelihood of 
metastasis developing, shrink tumor size, or slow tumor growth (André T. 2006; 
F.Giuliani 2010; Lombardi 2010). Despite the divergent treatment exist, the 
complete cure is rare and for cancer diagnosed at late stages (Cancer that 
metastasizes to distant sites (stage IV)) is usually not curable. Thus, 
adenocarcinoma is one of the most studied cancers by researchers. 
Here, we evaluated the effect of combined therapeutic treatment of pTNF 
polyplexes and Caelyx® in the intrasplenic liver metastatic colon 
adenocarcinoma model, and found the similar effect of inhibition of the tumor 
growth as in subcutaneous and metastatic murine Neuroblastoma. A possible 
reason for the therapeutic effect might be similar as mentioned in 4.10. As 
Bioluminescence imaging (BLI) results (fig. 11 A) and its quantification (fig. 11 
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B) shows, luminescence signals from tumors nodules are significantly lower in 
mice pTNF polyplexes/ Caelyx® treated than in mice pdeTNF poplyplexes/ 
Caelyx® treated or untreated. The photos of the mice body cavity (particularly 
the supposed metastasis organ liver and tumor cell inoculated organ spleen) at 
one day after last treatment showed that mice treated with 
pTNF/LPEI-PEG-GE11 polyplexes and Caelyx® do have significantly less 
metastatic tumors and reduced tumor growth (fig. 11 C); as well as the 
significantly lower weight of livers and spleens of mice (fig. 11 D). The reasons 
of the strong preference for generating liver metastases in this colon 
adenocarcinoma model could mainly due to the layout of the circulation 
(Christine L.Chaffer 2011): The disseminating colorectal cacinoma (CRC) cells 
may be intrinsically poorly adapted for survival in the liver microenvironment. 
However, because of the portal circulation, which drains from the mesentery 
directly into the liver, abundant carcinoma cells may be dumped over extended 
periods of time into the liver microvasculature; on rare occasion, an otherwise 
low-probability event may then generate a liver metastasis. In these various 
cases, homing to a particular organ can be considered to be a passive process 
that is determined by circulation patterns and the physical properties of the 
vasculature rather than by particular biological properties of the disseminating 
cancer cell (Christine L.Chaffer 2011).  
As our results showed, more than 70% of pTNF polyplexes/ Caelyx® treated 
mice showed significantly inhibition of tumor growth in spleen and metastasis in 
liver, while this was only rarely found in pdeTNF polyplexes/ Caelyx treated 
animals when compared to untreated animals (fig.11 D). Significantly lower 
Bioluminescence signal strength in the liver lysate which means significantly 
less tumor cells are found in the livers of pTNF poplyplexes/ Caelyx® treated 
mice than pdeTNF polyplexes/ Caelyx® treated or untreated mice (fig. 11E ). 
There was no complete tumor eradication in this model: only one mouse found 
in the pTNF poplyplexes/ Caelyx® treated group seems to have almost no 
tumors as detected by the BLI and visual inspection of the organs by eyes. 
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However when checking the spleen by HE staining, also tumors were found. As 
figures of HE staining showed, there were obviously large numbers of tumors 
metastases visible in the supposed metastatic organ liver and the tumor cells 
inoculated organ spleen in pdeTNF polyplexes/ Caelyx® treated or untreated 
mice, while the tumor metastases in livers from the pTNF polyplexes/ Caelyx® 
treated mice were significantly reduced, and the only one obvious tumor lesion 
found in one slice already developed necrosis with a relative small tumor size , 
which might be because the pTNF polyplexes and subsequently Caelyx® 
treatment induced the necrosis of tumor lesions at a relative early stage (fig. 11 
F-1). However, all spleens from three groups were seriously tumor infected (fig. 
11 F-2), although when observed by eyes, some mice from pTNF poplyplexes 
/Caelyx® treatment have only small tumors on the surface of spleen (fig. 11 C). 
These results might suggest that our treatment can not totally inhibit the tumor 
growth in mice in this metastatic intrasplenic liver metastatic colon 
adenocarcoma model.  
In conclusion, all these results from Bioluminescence, figures and weight of the 
tumor infected organs liver and spleen, and the HE staining of tissue section 
suggest that a pTNF polyplexes pretreatment and then Caelyx® chemotherapy 
do reduce the growth and metastasis of tumor cells in vivo in intrasplenic liver 
metastatic colon adenocarcinoma model, as well as in subcutaneous and 
metastatic murine neuroblastoma model, and that combining liposomal 
chemotherapeutic with TNF gene therapy leads to a synergistic effect on tumor 
reduction in vivo. However, how TNF gene therapy will help the chemotherapy 
in other cancers is still unknown and needs to be verified. 
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5. Summary 
Above a minimal size a tumor lesions relies on a functional blood supply, which 
gives access to oxygen and nutrients. This is achieved by the tumor cell‘s 
secretion of various pro-angiogenic factors. Albeit being well vascularized, solid 
tumor often exhibit a disorganized vessel structure and an increase interstitial 
pressure precluding efficient systemic treatment with chemotherapeutic drugs. 
Hypoxic conditions due to incomplete vasculatization can even turn cancer 
cells more aggressive and increase their metastatic potential (Vaupel 2008; 
Hoeckel 1996). In order to obtain an effective drug concentration in the tumor 
tissue, elevated doses have to be applied leading to unwanted side effects in 
non target organs. Hence, improving the accessibility of tumors for small and 
macromolecular chemotherapeutic drugs is hence a major aim in tumor therapy. 
One attempt to improve accumulation of anticancer drugs is to enhance the 
permeability of tumor blood vessels. This is especially of importance when 
applying macromolecular drugs, like liposomes or other particulate drug 
carriers, or even recombinant viruses used as gene carriers or virotherapy.  
An important endogenous mediator of inflammatory processes and endothelial 
permeability is the cytokine tumor necrosis factor alpha (TNFα). Tumor 
necrosis factor (TNF), as a major inflammatory cytokine involved in systemic 
inflammation, it can induce rapid haemorrhagic necrosis in experimental 
cancers. It was believed that recombinant human tumor necrosis factor (TNF) 
has pleiotropic properties; it has strong effects on angiogenic vessels in tumors, 
and the ability to cause apoptosis of tumor-associated endothelial cells which 
leads to the complete destruction of the tumor vasculature. In the study of ten 
Hagen‘s group, it was found that that applying low-dose tumor necrosis factor 
(TNF) by systemic injections with PEGylated long circulating liposomes 
augmented the tumor accumulation of these (Seynhaeve 2007). In addition, in 
the isolated limb perfusion, in which TNF is coadministered with a 
chemotherapeutic agent for the treatment of patients with limb threatening 
tumors, addition of TNF results in increased accumulation of drug inside the 
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tumor accompanied by improved response rates (van der Veen 2000; Hoving 
2006). In 1992, surgeons Ferdy Lejeune, Alexander Eggermont and their 
colleagues performed a local approach of TNF therapy, isolated limb perfusion 
(ILP), to deliver high doses of TNF in combination with IFNγ and melphalan 
locoregionally to patients with cancers of the extremities. This caused specific 
destruction of tumor vasculature, haemorrhagic necrosis and complete tumor 
disappearance in patients with advanced soft tissue sarcomas or melanoma 
(Lienard 1992; Grunhagen 2006). Also, a combination of TNF and doxorubicin 
treatment leads to comparable therapeutically effects in rat sarcoma model 
(van der Veen 2000). TNF treatment lead to an increase in endothelial 
permeability which subsequently induces the improvement of chemotherapy 
penetration within the tumor tissue; in addition, killing of angiogenic endothelial 
cells results in tumor vessel destruction (Seynhaeve 2007). 
However, the clinical use of TNF as an anti-cancer drug is limited to local 
treatments because of its dose-limiting systemic toxicity (Curnis Nov.2000). 
Systemic application of recombinant TNF is hampered by its high systemic 
toxicity dictating the need to target TNF activity selectively to the tumor. Here 
we demonstrate localized antitumor activity of TNF after systemic injection of a 
non viral, biodegradable gene carrier (G3-HD-OEI) exhibiting intrinsic tumor 
affinity in vivo in murine neuroblastoma model (Russ Dec 2008). We also used 
a novel TNF encoding plasmid with CpG free backbone and hCMV enhancer 
and EF1α promoter, since Stephen C Hyde et al observed that CpG-free 
plasmids with the hCMV/EF1α combination confer reduced inflammation and 
increase the magnitude and duration of gene expression in vivo (Hyde 2004).  A 
combination of TNF and doxorubicin had comparable effects in rat sarcoma 
models (van der Veen 2000). It appears that low doses of TNF increase tumor 
blood vessel permeability, thus augmenting tissue concentrations of 
chemotherapy (Seynhaeve 2007) and destroying the tumor vasculature 
(Colotta 1984).  
Here we found that when applying TNF encoding plasmid in a similar way, 
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inhibition of tumor growth was seen concomitant with decreased vessel density 
(CD31 expression). We could also show that systemic TNF gene delivery 
promoted tumor accumulation of liposomally encapsulated doxorubicine 
(Caelyx) in subcutaneous Neuro2A murine neuroblastoma and HUH7 human 
hepatocellular carcinoma. A/J mice bearing subcutaneous, syngeneic Neuro2A 
tumors were treated with polyplexes based on a biodegradable polymer 
(G3-HD-OEI), HUH7 hepatoma xenografts in SCID mice received TNF 
polyplexes based on linear polyethylenimine carrying a peptide (GE11) 
selectively binding to the epidermal growth factor receptor, which is highly 
overexpressed in HUH7. When pretreating mice with pTNF polyplexes, 
improved tumor accumulation of Caelyx® was observed in both tumor models 
as compared to control polyplexes plus Caelyx®. With the help of live 
bioluminescense imaging, enhanced tumor accumulation of Caelyx® 
fluorescently labeled with the lipid DiR emitting in the near infrared was 
observed. This suggests a TNF mediated increase of tumor blood vessel 
permeability augmenting the accumulation of liposomal chemotherapeutics. In 
the Neuro2A model, three rounds of systemic pTNF polyplexes application and 
subsequent Caelyx® treatment led to tumor growth inhibition lasting until eight 
days after the last treatment. Re-growth of treated tumors could be inhibited by 
a second treatment cycle indicating that no resistance towards combined pTNF 
polyplexes/ Caelyx® treatment occurred. Histological staining of cryosection 
showed significant decrease of CD31 expression in the re-treated group, which 
indicates a decreased vessel density caused by pTNF polyplexes/ Caelyx® 
treatment. Similar as in the subcutaneous model, in the murine metastatic 
neuroblastoma model, three rounds of systemic pTNF polyplexes application 
and subsequent Caelyx® treatment also led to tumor growth inhibition, as the 
bioluminescense signal signal of the luciferase marked tumor cells and the the 
total tumor burden are significantly lower than in pdeTNF polyplexes / Caelyx® 
(pdeTNF: control plsmid) treated or untreated mice. The photos of the body 
cavities also showed that mice treated with pTNF polyplexes and Caelyx® do 
Summary                                                                                                                                                 101 
have significantly less tumor metastases and the tumor growth was significantly 
reduced. Results of HE staining of livers from mice also showed that there are 
almost no tumor metastases remaining in pTNF polyplexes/ Caelyx® treated 
mice, while there are many tumor metastases were found in livers from pdeTNF 
polyplexes/Caelyx® treated and untreated mice. Moreover, when we applied 
the combined therapeutic treatment of pTNF polyplexes and Caelyx® in a 
intrasplenic liver metastatic colon adenocarcinoma model, a similar effect of 
inhibition of tumor growth as in murine neuroblastoma model was found. Both, 
the bioluminescense signal of lciferase marked tumors and the tumor weightis 
significantly lower in pTNF polyplexes/ Caelyx® treated mice than in pdeTNF 
polyplexes /Caelyx® treated or untreated mice. The photos of the body cavities 
(particularly the supposed metastasis organ liver and tumor cell inoculated 
organ spleen) showed that mice treated with pTNF polyplexes and Caelyx® do 
have significantly less metastatic tumor cells and exhibit a reduced tumor 
growth. Also, the weight of livers and spleens of mice were significantly 
decreased when compared to pdeTNF polyplexes/ Caelyx® treated or 
untreated mice. Consistently, significantly lower Bioluminescence signal 
strength in the liver lysate which means significantly less tumor cells in the 
livers are found in pTNF poplyplexes/Caelyx® treated mice than pdeTNF 
polyplexes/ Caelyx® treated or untreated mice. More than 70% of pTNF 
polyplexes/ Caelyx® treated mice showed significantly inhibition of tumor 
growth in spleen and metastasis in liver, while it was only rarely found in 
pdeTNF polyplexes/ Caelyx® treated mice. HE staining results showed that 
there were obviously large numbers of tumor metastases in livers from pdeTNF 
polyplexes/ Caelyx treated or untreated mice, while the tumor metastases in 
livers of pTNF polyplexes/ Caelyx® treated mice were significantly reduced, 
only a single tumor was found in one section, which already developed necrosis 
although being rather small in size. Spleens from three groups were seriously 
tumor infected, however, in pTNF poplyplex / Caelyx® treated mice, more 
tumor necrosis was observed.   
Summary                                                                                                                                                 102 
In conclusion, pTNF polyplexes pretreatment and subsequent Caelyx® 
chemotherapy does reduce the growth and metastasis of tumor cells in vivo in 
intrasplenic liver metastatic colon adenocarcinoma model, as well as in 
subcutaneous and metastatic murine neuroblastoma model, and that 
combining liposomal chemotherapeutic with TNF gene therapy leads to a 
synergistic effect on tumor reduction in vivo.  
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6. Appendix 
6.1. Abbreviations 
BLI, Bioluminescence imaging  
BSA, bovine serum albumin 
bPEI, branched PEI 
c/p-ratio, weight ratio of conjugate to plasmid 
CMV, Cytomegalovirus 
CpG, cytosine-guanine dinucleotide 
DMEM, Dulbecco s´ modified Eagle s´ medium 
DMSO, dimethyl sulfoxide 
DNA, deoxyribonucleic acid 
DiR, 1,1‘-dioctadecyl-3,3,3‘,3‘-tetramethylindotricarbocyanine iodide 
DAPI: 4',6-diamidino-2-phenylindole  
EGFP: Enhanced Green Fluorescent Protein 
E. coli, Escherichia coli 
EC, endothelial cell 
EF-1, elongation factor-1α 
eFLuc ,enhanced firefly luciferase 
ELISA, Enzyme-linked immunosorbent assay 
EGF, epidermal growth factor  
EGFP, enhanced green fluorescent protein 
FITC, fluoresceinisothiocyanate  
FCS, fetal calf serum 
Fig. ,figure 
Ex, excitation 
Em, emission 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase 
HBG, HEPES-buffered glucose 
hCMV, mCMV human, murine cytomegalovirus 
HEPES, N-(2-hydroxyethyl) piperazine-N‘-(2-ethansulfonic acid) 
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HD, hexandioldiacrylate 
HE stain, Hematoxylin Eosin stian 
ILP, isolated limb perfusion  
hCMV, human CMV 
i.p., intraperitoneal 
i.v., intravenous 
IFN, interferon 
IL, interleukin 
LPS, lipopolysaccharide 
LPEI, linear PEI 
miR, microRNA 
mCMV, murine CMV  
mRNA, messenger RNA 
MyD88, myeloid differentiation primary-response protein 88 
N/P-ratio, molar ratio of PEI nitrogen to DNA phosphate 
NFκB, nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NK, natural killer cell 
Ori, origin of replication 
OEI, oligoethylenimine 
PEI, polyethylenimine 
p/s, photons per second 
PBS, phosphate-buffered saline 
PCR, polymerase chain reaction 
PEG, polyethylene glycol  
pDNA, plasmid DNA 
PPI, polypropylenimine  
polyA, polyadenylation signal 
PSMC, porcine smooth muscle cell 
QPCR, real-time PCR 
RLU, relative light units 
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ROI, region of interest 
RNA, ribonucleic acid 
SCID, severe combined immunodeficiency  
TNF-α, tumor necrosis factor α 
UTR, untranslated region 
w/w, weight to weight ratio 
Zeo, zeosine resistance gene 
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6.2. Publications  
 
6.2.1. Poster presentations 
1. Su, Baowei, Russ, V, Carlsen, J, Wagner, E, Ogris, M. (2009) Non-viral 
tumor gene therapy with novel plasmids expressing the cytotoxic cytokine 
TNF-alpha. Combined Meeting of the 17th 
European-Society-of-Gene-and-Cell-Therapy/16thGerman-Society-for-Gen
e-Therapy/ 4thGerman-Society-for-Stem-Cell-Research NOV 21-25, 2009 
Hannover, GERMANY. Human Gene Therapy 20: 1421-1421. 
2. Su, Baowei, Wagner, E, Ogris, M. (2010) TNF Alpha Gene Therapy 
Synergizes with Liposomal Doxorubicin in the Treatment of Experimental 
Neuroblastoma and Hepatoma in Mice. 7th Annual Meeting of 
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